Feeds:
Posts
Comments

Archive for the ‘HTN’ Category

Preserved vs Reduced Ejection Fraction: Available and Needed Therapies

Reporter: Aviva Lev-Ari, PhD, RN

 

Ejection Fraction Heart Failure Measurement

Updated:Jul 9,2013

The ejection fraction (EF) is an important measurement in determining how well your heart is pumping out blood and in diagnosing and tracking heart failure.

A significant proportion of patients with heart failure happen to have a normal ventricular ejection fraction at echocardiography during examination. Previously called diastolic heart failure, it is nowadays referred to as heart failure with normal ejection fraction (HFNEF) or HF with preserved ejection fraction.

  1. Perserved ejection fraction (HFpEF) – also referred to as diastolic heart failure.  The heart muscle contracts normally but the ventricles do not relax as they should during ventricular filling (or when the ventricles relax).
  2. Reduced ejection fraction (HFREF) – also referred to as systolic heart failure.  The heart muscle does not contract effectively and less oxygen-rich blood is pumped out to the body.

What it is?
A measurement of how much blood the left ventricle pumps out with each contraction.

What it means.
An ejection fraction of 60 percent means that 60 percent of the total amount of blood in the left ventricle is pushed out with each heartbeat.

What’s normal?

  • A normal heart’s ejection fraction may be between 55 and 70.
  • You can have a normal ejection fraction reading and still have heart failure. If the heart muscle has become so thick and stiff that the ventricle holds a smaller-than-usual volume of blood, it might still seem to pump out a normal percentage of the blood that enters it. In reality, though, the total amount of blood pumped isn’t enough to meet your body’s needs.

What’s too low?

  • A measurement under 40 may be evidence of heart failure or cardiomyopathy.
  • An EF between 40 and 55 indicates damage, perhaps from a previous heart attack, but it may not indicate heart failure.
  • In severe cases, EF can be very low.

What’s too high?
EF higher than 75 percent may indicate a heart condition like hypertrophic cardiomyopathy.

Tests for measuring EF:

SOURCE
http://www.heart.org/HEARTORG/Conditions/HeartFailure/SymptomsDiagnosisofHeartFailure/Ejection-Fraction-Heart-Failure-Measurement_UCM_306339_Article.jsp

 

February 03, 2014

Both drug and device therapies have been shown to improve the outlook for patients with heart failure and reduced ejection fraction, but three leading cardiologists point to the lack of proven treatments for the other half of heart failure patients — those with preserved ejection fraction.

VIEW VIDEO

http://www.medpagetoday.com/HOTTOPICSWhatworksWhatDoesnt/special-reports/SpecialReports-Videos/394

SOURCE

From: MedPage Today <daily.headlines@medpagetoday.com>
To: <avivalev-ari@alum.berkeley.edu>

Heart Failure With Preserved Ejection Fraction

Circulation.2011; 124: e540-e543doi: 10.1161/​CIRCULATIONAHA.111.071696

 

  1. James E. Udelson, MD

+Author Affiliations


  1. From the Division of Cardiology and the CardioVascular Center, Tufts Medical Center, Boston, MA.
  1. Correspondence to James E. Udelson, MD, Tufts Medical Center, 800 Washington St, Box 70, Boston, MA 02111. E-mail judelson@tuftsmedicalcenter.org

 

Key Words:

It is now well established that among patients with the clinical syndrome of heart failure (HF), approximately half have preserved systolic function, known most commonly as heart failure with preserved ejection fraction (HFpEF). Although originally considered to be predominantly a syndrome that pathophysiologically involves abnormalities in diastolic function (relaxation and/or stiffness), ongoing investigation suggests that, although diastolic abnormalities may be present in many patients, other aspects of pathophysiology likely also contribute to symptoms.

Many recent articles have continued to explore aspects of this fascinating clinical syndrome. This review will summarize advances in understanding of the HFpEF syndrome, focusing on epidemiology, pathophysiology, and therapeutics.

Pathophysiology

Controversy continues regarding the prevalence of true abnormities of myocardial diastolic function in the syndrome of HFpEF. In a comprehensive invasive and noninvasive hemodynamic study in a group of highly selected patients with hemodynamically confirmed HFpEF, Prasad et al7 reported that compared with age-matched referent controls, increased static ventricular stiffness was not a universal finding in patients with HFpEF, although LV relaxation as assessed by tissue Doppler was consistently abnormal.

Substantial and growing attention has been given to the role of the cardiac interstitium in the pathophysiology of HFpEF. Zile and colleagues8 examined a panel of biomarkers for ability to discriminate symptomatic HFpEF from those with asymptomatic LV hypertrophy. This study showed that a panel of plasma biomarkers reflecting changes in extracellular matrix fibrillar collagen synthesis and degradation predicted the presence of HFpEF with an area under the curve of 0.79 and was more powerful than using N-terminal pro–B-type natriuretic peptide or clinical variables. Consistent with these findings, investigators from the Cardiovascular Health Study reported that biomarkers reflecting myocardial fibrosis, including carboxyl-terminal peptide of procollagen type I, carboxyl-terminal telopeptide of collagen type I, and amino-terminal peptide of procollagen type III, are significantly elevated in elderly patients with HFpEF and indeed are also elevated in those with systolic HF.9 Krum et al10 reported on a substudy from I-PRESERVE showing that increased baseline plasma levels of all collagen markers were associated with the I-PRESERVE primary outcome end point, although the relationship was not significant in a multivariable model. In a comprehensive human study, Westermann and colleagues11 interrogated the influence of cardiac inflammation on extracellular matrix remodeling in patients with HFpEF. Using endomyocardial biopsy samples to isolate primary human cardiac fibroblasts, the authors interrogated the gene expression of extracellular matrix proteins after stimulation with transforming growth factor-β. They reported an increase of cardiac collagen accompanied by a decrease in the collagenase system of the heart, as well as a correlation between cardiac collagen, inflammatory cells, and diastolic dysfunction. They concluded that inflammation contributes to diastolic abnormalities in HFpEF by stimulating extracellular matrix accumulation. All of these data suggest that the interstitium may be a promising therapeutic target if specific therapies can be deployed.

Although abnormalities in myocardial diastolic properties have been the focus of pathophysiological studies in patients with HFpEF in the past, many recent investigations have examined other structural and functional contributors. Kurt and colleagues12reported that HFpEF patients have similar LV mass and left atrial volume in comparison with patients with LV hypertrophy who are not in HF, although a measure of left atrial strain was reduced, and left atrial stiffness was useful in discriminating patients with HFpEF from those with LV hypertrophy without HF symptoms.

Several studies examined pathophysiology in HFpEF patients during exercise stress, which is when most patients have symptoms. Phan and colleagues13 reported that chronotropic incompetence, as measured by the percentage of the heart rate reserve used during maximal exercise, was more commonly present in patients with HFpEF compared with referent controls, as was abnormal heart rate recovery. Using dobutamine stress echocardiography with color tissue Doppler imaging, Chattopadhyay et al14 reported evidence of impaired diastolic reserve during stress, as well as stress-induced increase in the LV end-diastolic pressure, likely resulting in exercise intolerance because 6-minute walk distance was inversely correlated with the measures of diastolic function at rest and stress. Borlaug and colleagues15 examined hemodynamic responses to stress as a potential diagnostic approach in patients with exertional dyspnea, in whom making a specific diagnosis may be challenging. The investigators studied patients with exertional dyspnea, preserved EF, normal brain natriuretic peptide levels, and normal resting hemodynamics. Exercise-induced elevation in pulmonary capillary wedge pressure was used to define HFpEF and was associated with blunted increases in heart rate and cardiac output and blunted systemic vasodilation. An exercise pulmonary artery systolic pressure ≥45 mm Hg identified HFpEF with 96% sensitivity and 95% specificity. These data suggest that patients who present a challenge for specific diagnosis should undergo an exercise hemodynamic study.

Two studies examined clinical or echocardiographic variables that might be useful in estimating LV filling pressures in patients with HFpEF. Drazner et al16 reported that right atrial pressures often reflected left-sided filling pressures in HFpEF, suggesting that estimation of jugular venous pressure could be used to assess volume status. However, the echocardiographic indexes E/e′ and E/Vp did not appear to reliably track changes in left-sided filling pressures in patients with HFpEF.17

Studies using translational models explored the underlying mechanism of the transition from compensated LV hypertrophy to a state of HF. In a transverse aortic constriction model adding mineralocorticoid (deoxycorticosterone acetate) excess, Mohammed et al18reported that mice treated with deoxycorticosterone acetate showed progressive activation of markers of oxidative stress but no evidence of mineralocorticoid receptor–dependent gene transcription. They concluded that pressure-overload hypertrophy sensitizes the heart to mineralocorticoid excess and that the transition to HF with preserved EF is associated with mechanisms independent of mineralocorticoid receptor–dependent gene transcription. In a study of cardiac energy metabolism in which Dahl salt-sensitive rats fed a high-salt diet were used to drive a transition from compensated LV hypertrophy to HF, Kato and colleagues19 reported that glucose uptake increased with LV hypertrophy and further increased at the HF stage, with decreased fatty acid uptake and corresponding changes in gene expression related to the metabolic pathways as well as mitochondrial function with the onset of HF. Dichloroacetate, which enhances glucose oxidation, attenuated the transition to HF, associated with increased energy reserves and reduced oxidative stress. The data from these models suggest potential therapeutic directions for the future, although mineralocorticoid receptor antagonism is already under comprehensive study.

Therapeutics

As noted, large randomized trials in broad populations of patients with HFpEF in which agents such as angiotensin receptor blockers were used have generally shown neutral results. Smaller trials continue to explore potential therapeutic directions for this challenging-to-manage syndrome. Kitzman and colleagues20 randomized 71 elderly HFpEF patients with compensated symptoms and controlled blood pressure into a 12-month follow-up double-blind trial of enalapril 20 mg/d versus placebo.

There was no effect of the angiotensin-converting enzyme inhibitor on

  • the primary end point of peak exercise oxygen consumption and
  • no effect on multiple secondary end points including 6-minute walk distance,
  • aortic distensibility,
  • LV mass, or
  • neurohormones.

The findings are consistent with the longer-term natural history outcomes of angiotensin receptor blocker trials.

Many of the same authors examined a nonpharmacological approach in a 16-week randomized study of supervised exercise training in 53 elderly patients with HFpEF.21The primary outcome was peak exercise oxygen uptake, which increased significantly in the exercise group compared with the control group (2.3±2.2 versus −0.3±2.1 mL/kg per meter; P=0.0002). Many secondary end points were also improved, including exercise time, 6-minute walk distance, and ventilatory anaerobic threshold. In contrast to some trials of exercise training, a key to the favorable results of this study may have been the good compliance with the exercise training regimen among the enrolled patients. These important data suggest an important therapeutic direction.

Favorable results were also seen in a small study involving an important subgroup of HFpEF patients, those with pulmonary hypertension. Guazzi and coworkers22 randomized 44 such patients to sildenafil at a dose of 50 mg 3 times per day or to placebo for 6 months. At the end of the trial, sildenafil was associated with decreased mean pulmonary artery and reduced right atrial pressure and improved right ventricular function. They also reported reduced lung water content and improved alveolar-capillary gas conductance, as well as improved measure of left-sided systolic and diastolic cardiac function. Results were maintained at 12 months.

Hence, although large trials using neurohormonal antagonists that have been favorable in HF with reduced EF have not shown favorable results in HFpEF, these early studies suggest promising therapeutic directions to explore. Such studies also enhance our understanding of pathophysiology and point the way to larger and more definitive investigations.

SOURCE
REFERENCES
  1. 1.↵
    1. Lewis EF,
    2. Solomon SD,
    3. Jablonski KA,
    4. Rice MM,
    5. Clemenza F,
    6. Hsia J,
    7. MaggioniAP,
    8. Zabalgoitia M,
    9. Huynh T,
    10. Cuddy TE,
    11. Gersh BJ,
    12. Rouleau J,
    13. Braunwald E,
    14. Pfeffer MA

    ,on behalf of the PEACE Investigators. Predictors of heart failure in patients with stable coronary artery disease. Circ Heart Fail. 2009;2:209–216.

  2. 2.↵
    1. Lee DS.,
    2. Gona P,
    3. Vasan RS,
    4. Larson MG,
    5. Benjamin EJ,
    6. Wang TJ,
    7. Tu JV,
    8. Levy D

    .Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation. 2009;119:3070–3077.

  3. 3.↵
    1. Zile MR,
    2. Anand IS,
    3. Gaasch WS,
    4. Haass M,
    5. Little WC,
    6. Miller AB,
    7. Lopez-Sendon J,
    8. Teerlink JR,
    9. White M,
    10. McMurray JJ,
    11. Komajda M,
    12. McKelvie R,
    13. Ptaszynska A,
    14. Hetzel SJ,
    15. Massie BM,
    16. Carson PE

     for the I-Preserve Investigators. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PRESERVE) Trial. Circulation.2010;121:1393–1405.

  4. 4.↵
    1. Komajda M,
    2. Carson PE,
    3. Hetzel S,
    4. McKelvie R,
    5. McMurray JJ,
    6. Ptaszynska A,
    7. ZileMR,
    8. DeMets D,
    9. Massie BM

    . Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail. 2011;4:27–35.

  5. 5.↵
    1. Haass M,
    2. Kitzman DW,
    3. Anand IS,
    4. Miller A,
    5. Zile MR,
    6. Massie BM,
    7. Carson PE

    . Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction (I-PRESERVE) Trial. Circ Heart Fail. 2011;4:324–331.

  6. 6.↵
    1. Curtis LH,
    2. Greiner MA,
    3. Shea AM,
    4. Whellan DJ,
    5. Hammill BG,
    6. Schulman KA,
    7. DouglasPS

    . Assessment of left ventricular function in older Medicare beneficiaries with newly diagnosed heart failure. Circ Cardiovasc Qual Outcomes. 2011;4:85–91.

  7. 7.↵
    1. Prasad A,
    2. Hastings JL,
    3. Shibata S,
    4. Popovic ZB,
    5. Arbab-Zadeh A,
    6. Bhella PS,
    7. Okazaki K,
    8. Fu Q,
    9. Berk M,
    10. Palmer D,
    11. Greenberg NL,
    12. Garcia MJ,
    13. Thomas JD,
    14. Levine BD

    .Characterization of static and dynamic left ventricular diastolic function in patients with heart failure with a preserved ejection fraction. Circ Heart Fail. 2010;3:617–626.

  8. 8.↵
    1. Zile MR,
    2. DeSantis SM,
    3. Baicu CF,
    4. Stroud RE,
    5. Thompson SB,
    6. McClure CD,
    7. MehurgSM,
    8. Spinale FG

    . Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail. 2011;4:246–256.

  9. 9.↵
    1. Barasch E,
    2. Gottdiener JS,
    3. Aurigemma G,
    4. Kitzman DW,
    5. Han J,
    6. Kop WJ,
    7. Tracy RP

    .Association between elevated fibrosis markers and heart failure in the elderly: the Cardiovascular Health Study. Circ Heart Fail. 2009;2:303–310.

  10. 10.↵
    1. Krum H,
    2. Elsik M,
    3. Schneider HG,
    4. Ptaszynska A,
    5. Black M,
    6. Carson PE,
    7. KomajdaM,
    8. Massie BM,
    9. McKelvie M,
    10. McMurray JJ,
    11. Zile MR,
    12. Anand I

    . Relation of peripheral collagen markers to death and hospitalisation in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE Collagen Sub-Study. Circ Heart Fail.2011;4:561–568.

  11. 11.↵
    1. Westermann D,
    2. Lindner D,
    3. Kasner M,
    4. Zietsch C,
    5. Savvatis K,
    6. Escher F,
    7. von Schlippenbach J,
    8. Skurk C,
    9. Steendijk P,
    10. Riad A,
    11. Poller W,
    12. Schultheiss H-P,
    13. Tschöpe C

    .Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail. 2011;4:44–52.

  12. 12.↵
    1. Kurt M,
    2. Wang J,
    3. Torre-Amione G,
    4. Nagueh SF

    . Left atrial function in diastolic heart failure. Circ Cardiovasc Imaging. 2009;2:10–15.

  13. 13.↵
    1. Phan TT,
    2. Shivu GN,
    3. Abozguia K,
    4. Davies C,
    5. Nassimizadeh M,
    6. Jimenez D,
    7. WeaverR,
    8. Ahmed I,
    9. Frenneaux M

    . Impaired heart rate recovery and chronotropic incompetence in patients with heart failure with preserved ejection fraction. Circ Heart Fail.2010;3:29–34.

  14. 14.↵
    1. Chattopadhyay S,
    2. Alamgir MF,
    3. Nikitin NP,
    4. Rigby AS,
    5. Clark AL,
    6. Cleland JGF

    . Lack of diastolic reserve in patients with heart failure and normal ejection fraction. Circ Heart Fail. 2010;3:35–43.

  15. 15.↵
    1. Borlaug BA,
    2. Nishimura RA,
    3. Sorajja P,
    4. Lam CSP,
    5. Redfield MM

    . Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction.Circ Heart Fail. 2010;3:588–595.

  16. 16.↵
    1. Drazner MH,
    2. Prasad A,
    3. Ayers C,
    4. Markham DW,
    5. Hastings J,
    6. Bhella PS,
    7. Shibata S,
    8. Levine BD

    . The relationship of right- and left-sided filling pressures in patients with heart failure and a preserved ejection fraction. Circ Heart Fail. 2010;3:202–206.

  17. 17.↵
    1. Bhella PS,
    2. Pacini EL,
    3. Prasad A,
    4. Hastings JL,
    5. Adams-Huett B,
    6. Thomas JD,
    7. Grayburn PA,
    8. Levine BD

    . Echocardiographic indices do not reliably track changes in left-sided filling pressure in healthy subjects or patients with heart failure with preserved ejection fraction. Circ Cardiovasc Imaging. 2011;4:482–489.

  18. 18.↵
    1. Mohammed SF,
    2. Ohtani T,
    3. Korinek J,
    4. Lam CSP,
    5. Larsen K,
    6. Simari RD,
    7. ValencikML,
    8. Burnett JC,
    9. Redfield MM

    . Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via “nongenomic effects.” Circulation. 2010;122:370–378.

  19. 19.↵
    1. Kato T,
    2. Niizuma S,
    3. Inuzuka Y,
    4. Kawashima T,
    5. Okuda J,
    6. Tamaki Y,
    7. Iwanaga Y,
    8. Narazaki M,
    9. Matsuda T,
    10. Soga T,
    11. Kita T,
    12. Kimura T,
    13. Shioi T

    . Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ Heart Fail.2010;3:420–430.

  20. 20.↵
    1. Kitzman DW,
    2. Hundley WG,
    3. Brubaker PH,
    4. Morgan TM,
    5. Moore JB,
    6. Stewart KP,
    7. Little WC

    . A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility.Circ Heart Fail. 2010;3:477–485.

  21. 21.↵
    1. Kitzman DW,
    2. Brubaker PH,
    3. Morgan TM,
    4. Stewart KP,
    5. Little WC

    . Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail. 2010;3:659–667.

22.↵

  1. Guazzi M,
  2. Vicenzi M,
  3. Arena R,
  4. Guazzi MD

. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124:164–174.

Read Full Post »

Requiem for Palliative Cardiology: The Voice of Dr. Esselstyn on Plant-Based Nutrition

Reporter: Aviva Lev-Ari, PhD, RN

 

SELECTED ARTICLES BY DR. ESSELSTYN

 

Articles on the Arrest and Reversal Study:

Selected Articles:

Reflections and News:

Video:

SOURCE

http://www.heartattackproof.com/articles.htm

EXCERPT from
PREVENT AND REVERSE HEART DISEASE 

by Caldwell B. Esselstyn, Jr., MD

Chapter One
Eating to Live

I believe that coronary artery disease is preventable, and that even after it is underway, its progress can be stopped, its insidious effects reversed. I believe, and my work over the past twenty years has demonstrated, that all this can be accomplished without expensive mechanical intervention and with minimal use of drugs. The key lies in nutrition—specifically, in abandoning the toxic American diet and maintaining cholesterol levels well below those historically recommended by health policy experts.

The bottom line of the nutritional program I recommend is that it contains not a single item of any food known to cause or promote the development of vascular disease. I often ask patients to compare their coronary artery disease to a house fire. Your house is on fire because eating the wrong foods has given you heart disease. You are spraying gasoline on the fire by continuing to eat the very same foods that caused the disease in the first place.

I don’t want my patients to pour a single thimbleful of gasoline on the fire. Stopping the gasoline puts out the fire. Reforming the way you eat will end the heart disease.

Here are the rules of my program in their simplest form:

• You may not eat anything with a mother or a face (no meat, poultry, or fish).

• You cannot eat dairy products.

• You must not consume oil of any kind—not a drop. (Yes, you devotees of the Mediterranean Diet, that includes olive oil, as I’ll explain in Chapter 10.)

• Generally, you cannot eat nuts or avocados.

You can eat a wonderful variety of delicious, nutrient-dense foods:

• All vegetables except avocado. Leafy green vegetables, root vegetables, veggies that are red, green, purple, orange, and yellowand everything in between

• All legumes—beans, peas, and lentils of all varieties.

• All whole grains and products, such as bread and pasta, that are made from them—as long as they do not contain added fats.

• All fruits.

It works. In the first continuous twelve-year study of the effects of nutrition in severely ill patients, which I will describe in this book, those who complied with my program achieved total arrest of clinical progression and significant selective reversal of coronary artery disease. In fully compliant patients, we have seen angina disappear in a few weeks and abnormal stress test results return to normal.

SOURCE

Q&A with Caldwell B. Esselstyn, Jr., MD


Caldwell B. Esselstyn, Jr., MD, F.A.C.S.

Please note: If your question is about finding a doctor in your area who supports a plant-based diet, please see this link: How to Find a Plant-Based Doctor.

1. How is your approach to treating heart disease unique?

My program is a nutrition-based therapy that has been scientifically-proven to reverse heart disease. There is no other treatment plan backed by a study as long as the one I conducted, or a study that has produced such dramatic, visible results. Coronary angiograms (X-Rays) of the patients in my study show an actual reversal of the disease. To experience these benefits, my patients must stick to my plant-based diet program strictly, but the effects are more than worth the effort. For those that are very sick, it is the most effective treatment option–far less dangerous and more effective than invasive surgical procedures such as stents and bypass (except in acute emergencies), and much more effective than drugs alone. Traditional cardiology has relied on technology to ease the symptoms of heart disease, but has not addressed its causes. My approach is not another stop-gap solution, it prevents heart disease from occurring in those who don’t yet have the disease, and it heals the body and reverses the disease when symptoms are present.

Best of all, over time the benefits endure and continue to improve. I am always excited when I see arrest and reversal in patient after patient and their joy and relief when they are free of the disease that was destroying them.

2. What would you say to someone considering a stent or other surgical procedure or drug therapy, to treat their heart disease?

All heart patients who are not absolute emergencies should first have an aggressive opportunity at non surgical medical therapy. This is not just my opinion but that of expert cardiolgists from Boston, Hartford, Houston, Stanford, San Diego, Seattle and Cleveland. The difference in my case is that I advocate an aggressive plant based nutrition program to arrest and reverse the disease and to avoid all surgery. Drugs alone do not prevent heart attacks and stop symptoms of heart disease.

3. How do you encourage your patients to stay on the diet?

There is no question it is hard at first. And it is hardest eating out at friends’ houses. However, I am always impressed how well my patients do once they experience the relief of chest pain, weight loss, and the improved feeling of well being they have eating a plant-based diet. Then the motivation comes from within. It also helps that within 8-12 weeks of starting the program the fat receptor in the brain down regulates and they lose the craving for fat. And as they start feeling better and better, they know that they are the ones– not their physician or their surgeon–that have control over the disease. It is a powerful feeling!

4. Why does the diet eliminate oil entirely?

NO OIL! Not even olive oil, which goes against a lot of other advice out there about so-called good fats. The reality is that oils are extremely low in terms of nutritive value. They contain no fiber, no minerals and are 100% fat calories. And above all they contain saturated fat which immediately injures the endothelial lining of the arteries when eaten. It doesn’t matter whether it’s olive oil, corn oil, coconut il or any other kind , avoid ALL oil. This is so important I have detailed oil in Chapter 10.

5. Can you actually enjoy food on the program?

We LOVE our food. Our children and grandchildren love our food and the patients love the food. Everyone loves the food once they give it a try. It is all a matter of attitude–and you do need a positive attitude to get started and to understand that this new way of eating is the best thing you can do for your body. Then, the body will help you adjust. You actually begin to lose your physiologically-based craving for fat. Once that occurs, you can fully appreciate the natural taste of plant foods–the colorful tastes and textures are difficult to surpass.

6. Why should I change? My health is excellent.

No one escapes in the end–eventually the traditional western diet guarantees some form of disease in all of us. While it may not be heart disease at the moment, eventually it will be or hypertension, diabetes, stroke,obesity, gall stones, diverticulitis, rheumatoid arthritis, lupus, multiple sclerosis, or a greater likelihood of breast, prostate, colon, ovarian and uterine cancers. Even erectile dysfunction and dementia. The world famous Framingham Heart Study now approaching its 60th year looked at 1,000 people at age 50 who had normal blood pressure. They looked at the same group at age 70, and 90% now had high blood pressure. But there is something that you can do now to stop the cascading events that occur in the body and lead to disease. You can change your diet and begin safeguarding your health for the future.

More Commonly Asked Questions

Protein – Where do I get my protein / What protein drink is best? 
Extra protein powder and shakes are truly unnecessary and have the potential for harm if they contain animal protein. The protein available in a diet of whole grains, legumes and beans, and red, yellow and green vegetables is adequate to nourish even professional champion athletes such as the iron man, professional football, mixed marshal arts, track and field,

Calcium – Where do I get calcium?
Calcium supplementation is unnecessary. There is more than adequate calcium in a plant- based diet of whole grains, legumes and grains and especially the green leafy vegetables.

Vitamins – What Vitamins should I take?
Take Vitamin B-12. If eating copious amounts of leafy green vegetables, a multi vitamin is unnecessary. Have blood tested for Vitamin D level and supplement as appropriate to maintain blood level in the normal range.

Fish Oil – Should I take fish oil?
Fish oil is not essential. Fish get their omega 3 from plants. It is difficult to be deficient in Omega 3 if eating 1-2 tablespoons of flax seed meal or chia seeds and green leafy vegetables at several meals. There is also research that suggests that those on plant based nutrition become highly efficient in their own manufacture of omega 3. Patients on fish oil are also at increased risk for bleeding.

Flax Seed Oil/ Flax Seed Meal – What about flax seed oil?
Flax seed meal is well tolerated and supplies a bonus of omega 3 using 1 or 2 tablespoons on cereal daily. Avoid flax seed oil.

Olive oil, canola oil, coconut oil, Sunflower oil, soybean oil, peanut oil, any oil –
Which oil is best?

Avoid oils. They injure the endothelium, the innermost lining of the artery, and that injury is the gateway to vascular disease. All oil is also empty calories.

Lotions with oil – Is it all right to use lotions with oil on my skin?
It is fine to use lotions with oil on your skin.

Omega 3 – How do I get my Omega 3’s?
Omega 3’s are essential fatty acids supplied in adequate amounts in people consuming plant based nutrition with plenty of green leafy vegetables. However 1-2 tablespoons of flax seed meal or chia seeds daily is perfectly accepted.

Family history – I have a bad family history? Does it matter?
Our data indicates even those with strong family history when eating plant based are protected from vascular disease. Family history loads the gun but lifestyle pulls the trigger.

Nuts – What about nuts? I hear so many different opinions.
My preference is no nuts for heart disease patients. That also eliminates peanuts and peanut butter even though peanuts are officially a legume. For those with established heart disease to add more saturated fat that is in nuts is inappropriate. For people with no heart disease who want to eat nuts and avocado and are able to achieve a cholesterol of 150 and LDL of 80 or under without cholesterol lowering drugs, some nuts and avocado are acceptable. No nuts for heart disease patients, includes peanuts and peanut butter, even though peanuts are officially a legume. Chestnuts are the one nut, very low in fat, it is ok to eat.

Seeds (sunflower, pumpkin, sesame, etc.) Are seeds ok to eat?
1 -2 tablespoons of ground flax seeds or chia seeds daily for omega 3 are appropriate for everyone to eat including heart patients if they wish. Some seeds baked in bread or crackers is acceptable. Just don’t eat handfuls.

Coconut water – Is it all right to drink coconut water?
Coconut water is 8% saturated fat (If the fat is less than .5 per serving it does not have to be listed on the label) and about 50% sugar. So save your money and don’t use it.

Prostate cancer- Does plant based eating help prostate cancer?
Prostate cancer is greatly lessoned by plant- based nutrition as best exemplified by the 1958 report confirming by autopsy 18 deaths in the entire nation of Japan.

Egg whites, fat free milk, yogurt – So What is wrong with egg whites, fat free yogurt, skim milk?
Egg whites, fat free milk and yogurt are ALL animal protein, and animal protein injures the lining of the arteries. Do not eat.

Cholesterol Number fluctuation – Why do my cholesterol numbers fluctuate? 
Fluctuation of cholesterol is normal. It is nice to have it fluctuating in a range that would indicate you are unlikely to have cardio vascular problems.

Losing weight – What can I do to stop losing too much weight?
If you are losing too much weight, EAT MORE calories. Increase portion size. Eat snacks. Eat more whole grains and beans.

Tired, no energy – Why am I tired and have no energy since eating plant-based? 
If you feel tired and lacking in energy, be sure you are eating enough calories. Also exercise because you need to use energy to make energy. Depression also contributes to lack of energy. But first of all eat more.

Not losing weight – Why haven’t I lost weight/ Why have I stopped losing weight?
If not losing enough weight, eliminate flour products like bread, pasta and bagels. Instead, eat whole grains like rice, quinoa, barley and farro, etc. Reduce portion size. Increase leafy green vegetables and exercise.

Triglycerides- Why did my triglycerides go up?
If your triglycerides are high, cut back on simple carbohydrates, which would include alcohol, wine, beer, white flour products, sugars including dried fruit, honey maple syrup, molasses, rich desserts, fruit juice or an excess of fruit,

HDL- My doctor is so concerned because my HDL has gone down
It is not uncommon for HDL to fall when consuming plant based nutrition. Do not be alarmed. The capacity of HDL to do its job has been shown recently by scientific research that there is no relationship between the capacity of the HDL molecule to function optimally and its blood level. Recent research has confirmed that the HDL molecule can be injured and weakened when one is ingesting a pro inflammatory western diet and conversely it appears despite a lower than normal level to be optimized by anti inflammatory plant based-nutrition.

LDL – Where should my LDL be?
LDL is the bad cholesterol. The closer it can be to 80-85, the better. However, if one is unable to take statin drugs and eating plant-based nutrition, and the LDL won’t go lower than 95-105, it would appear that they will still be fine. The lesson we learned from the Tarahumara Indians, who never have cardiovascular disease, is that the most key protective element is not so much the pure LDL number as is knowing that nothing ever is eaten which is a building block of vascular disease or can injure endothelium.

Statins – Should I take statins or not?
Statins are not the reason that cultures such as the Tarhumara and the Papua Highlanders do not have cardiovascular disease. Statins appear to have minimal if any benefit in primary prevention but are of some help in slowing disease progression for those who already have an established diagnosis of cardiovascular disease. Clearly some of our most profound successes in arresting and reversing disease were with patients who either refused or were incapable of taking statins. Nothing is as powerful for the prevention of cardiovascular disease as plant based nutrition.

Coumadin – Can I eat leafy greens when I am on Coumadin?
Coumadin (Warfarin) is an anti clotting drug shown to have significant benefit in protecting people with atrial fibrillation from having a stroke. Can patients on Coumadin eat all the green leafy vegetables with vitamin k, which may shorten their clotting time? The answer most emphatically is YES! Merely inform the physician who is monitoring the Coumadin and clotting time that you are regularly going to be eating copious amounts of healthy green leafy vegetables. He/she will appropriately adjust the Coumadin dose.

Juicing- Is it all right to juice?
Do not juice. You lose all the fiber and its benefits.

Fruit juice – What about fruit juice?
Drinking fruit juice is like pouring the sugar bowl down your throat. It is fine to eat the whole fruit. Do not drink the juice.

Smoothies – How about smoothies? I love them! 
Avoid smoothies. The fiber is so finely pureed that its helpful properties are potentially compromised. The sugar is separated from the fiber of the fruit, bypasses salivary digestion and results in a surge of glucose. The accompanying fructose contributes to inflammation, hypertension and endothelial injury.

A Fib- Will plant nutrition work for A Fib?
While A Fib is largely independent of nutrition, and is a heart rhythm abnormality, there are some subset of cases which are presumably related to less than optimal heart circulation. While it would be totally inappropriate for me to suggest plant – based nutrition would cure atrial fibrillation, the many ancillary benefits would indicate plant based nutrition would be of value.

Calcium score- Is a calcium score helpful?
With cardiac CT you get a big hit of radiation. If you have been eating the typical American diet, you already have heart disease as autopsy studies have shown.

SOURCE

http://www.heartattackproof.com/qanda.htm

Caldwell B. Esselstyn, Jr
Speaking Schedule 2014

Engine 2 “Farms 2 Forks” Immersions – A chance to spend two days with Dr. Esselstyn

Join Dr. Esselstyn, his wife Ann, his son Rip, and his daughter Jane at the Engine 2/Forks Over Knives’/”Farms 2 Forks” weekend retreats!  For three days, you can learn the medical, nutritional, psychological, and practical tools that you and your family can turn into a lifetime of good health and enjoyable food.   Joining the Esselstyn’s at events will be nutrition expert, Michael Greger MD, and Dr. Doug Lisle, food psychologist and author of “The Pleasure Trap”.  Special guest speakers will include Dr. Neal Barnard, Dr. John McDougall, and T. Colin Campbell.

For more information or to register, visit the event website at www.farms2forks.com.

Wednesday, February 5, 2014
Columbia Presbyterian Grand Rounds
Myrna Daniels Auditorium, 1st floor
Vivian & Seymour Milstein Family Heart Center
173 Fort Washington Ave
New York City
12:00pm-1:00pm
Open to the public
Tuesday, February 11, 2014 Essy
Cooper Clinic
Dallas, Texas
4:00-5:00
for details contact Christine Dicken
at 972-560-2667

Tuesday, February 18, 2014 E&A
Twinsberg Library
Twinsberg, Ohio
7:00 pm

Friday, February 21- Sunday, 23, 2014 E&A
McDougal Advanced Study Weekend
Santa Rosa, California
800-941-7111 for details

February 28th — March 2nd, 2014 E&A
Engine 2 Phoenix Retreat
Hyatt Regency Phoenix
122 North Second Street
Phoenix, AZ 85004 Engine 2 and Forks Over Knives are kicking off the 2014 series in beautiful, sunny Phoenix, and are sure the warm, inviting February weather will bring people from across the country for a weekend of inspiration and change in the desert. We will be gathering at the Hyatt Regency, right in the middle of cosmopolitan downtown Phoenix, with easy access to the airport and everything that the city has to offer. With the Esselstyn family leading the way, we will tackle a myriad of topics designed to increase your plant-based knowledge, and send you home overflowing with information for yourself, your loved ones, your coworkers, and anyone else you encounter!
For details: www.engine2diet.com

Tuesday, March 11, 2014 Essy
Cleveland Clinic
Cleveland, Ohio
Lerner NA5-08
12:00-1:00

Wednesday, March 19, 2014 Essy
Cleveland Clinic
Pediatric Grand Rounds
A 11 800 conference room
4:00 pm

Thursday, March 27, 2014 Essy
Drury University
Springfield, Missouri
Health Care Forum
Details:417-880-5001

Friday, April, 18, 2014 Essy
Mayo Clinic
Rochester, Minnesota
7:30 -8:30 am

April 25th — April 27th, E&A
Engine 2 Retreat Portland
2014 Hilton Portland & Executive Tower
921 Sixth Avenue
Portland, OR 97204
If you haven’t been to Portland, Oregon, you are really missing out. Wait, here’s your chance! Engine 2 and Forks Over Knives are thrilled to bring an Engine 2 Retreat weekend to one of the most beautiful, green, and spectacular cities is America. We are setting up shop right smack in the middle of downtown Portland, which lies in the shadow of the majestic and awe-inspiring Mount Hood. Our location is an easy walking distance from all of the coffee shops, eclectic stores, and vibrant culture that this most “European” of American cities has to offer.
For details: www.engine2diet.com

Saturday, May 3, 2014 Essy
Iowa Osteopathic Association
DeMoine, Iowa
Embassy Suite Hotel
9:00

Thursday, May, 15- Sunday, May 17 E&A
Gold Symposium
Boulder, Colorado
Details: 303-625-2098

Sunday, May 18- Thursday May 22 E&A
Engine 2 Retreat Sedona
Sedona Hotel
3500 E. Bill Gray Road
Sedona, AZ 86336
Rip Esselstyn invites you to join Engine 2 and Whole Foods Market team members in Sedona, Arizona in 2014 for a weeklong immersion intensive retreat, scheduled for May 17th — 23rd at the Sedona Mago Retreat Center. Featuring the all-star cast from our sold-out Engine 2 Retreat Weekends, this 7-day/6-night life-changing week will give you an in-depth medical & nutritional education about why & how to adopt a plant-strong lifestyle. In addition, the curriculum delves deeply into the psychological and practical methods & practices for successfully implementing sustainable lifestyle changes, with multiple lectures and breakout sessions led by esteemed doctor Caldwell B. Esselstyn, famed nutritionist Michael Greger, and renowned psychologist Doug Lisle.
For details: www.engine2diet.com

June 27th – 29th, 2014 E&A
Engine 2 Retreat Chicago
Double Tree Chicago – Oak Brook
1909 Spring Rd
Oak Brook, IL 60523
Engine 2 and Forks Over Knives are thrilled to return to the Windy City for another wonderful inspiring and motivating plant-strong Engine 2 Retreat. We can’t get enough of the warm & welcoming midwestern hospitality, and we enjoy returning here each year. This year we’ll be just west of downtown Chicago in the wonderful suburb of Oak Brook, IL. With Rip as your host, we will tackle a myriad of topics designed to increase your plant-based knowledge. More
For details: engine2diet.com

August 16th – 17th, 2014
The Ultimate Weekend Experience: Plant-Stock E&A
Engine 2 Retreat Claverack
Esselstyn Family Farm
56 Willowdale Farms
Claverack, NY 12513 On the Esselstyn family’s idyllic 400-acre farm in the beautiful Catskills, “Plant-Stock” brings you the ultimate plant-strong experience. We have lined up a rockstar roster to motivate and inspire you to take back your health. The weekend will feature all the plant-strong heavyweights, including Dr. Caldwell B. Esselstyn, Jr., T. Colin Campbell, Michael Moss, and many more special guests to be announced throughout the coming year. A rousing success last year, the event created a whole network of plant-strong ambassadors. We hope you will join us, take this information home with you, and put it into practice with your family, friends, and community! Be the change.
For details: engine2diet.com

Sunday, September 8 E&A
Aspen Valley Hospital Cardiac Rehab opening
Aspen, Colorado
1:00-4:00

Friday, September 12 – Sunday September 14, 2014 E&A
Engine 2 Immersion
Austin, Texas
Details:engine2.com

Thursday, September 18 – Saturday September 20 Essy
Plant Based National Health Conference
San Diego, California

October 12th – 18th, 2014 E&A
E2 Weeklong Immersion Intensive: Sedona, Arizona
Sedona Hotel
3500 E. Bill Gray Road
Sedona, AZ 86336
Rip Esselstyn invites you to join Engine 2 and Whole Foods Market team members in Sedona, Arizona in 2014 for a weeklong immersion intensive retreat, scheduled for October 12th – 18th at the Sedona Mago Retreat Center. Featuring the all-star cast from our sold-out Engine 2 Retreat Weekends, this 7-day/6-night life-changing week will give you an in-depth medical & nutritional education about why & how to adopt a plant-strong lifestyle. In addition, the curriculum delves deeply into the psychological and practical methods & practices for successfully implementing sustainable lifestyle changes, with multiple lectures and breakout sessions led by esteemed doctor Caldwell B. Esselstyn, Jr.famed nutritionist Michael Greger, and renowned psychologist Doug Lisle.
For details: engine2diet.com

Wednesday, October 23 – Sunday, October 26 E&A
Lithuania

 SOURCE

http://www.heartattackproof.com/speaking_dates.htm

Read Full Post »

Prolonged Wakefulness: Lack of Sufficient Duration of Sleep as a Risk Factor for Cardiovascular Diseases – – Indications for Cardiovascular Chrono-therapeutics

Curator: Aviva Lev-Ari, PhD, RN

This article has the following structure:

  • Sleep Drives Metabolite Clearance from the Adult Brain
  • Sleep and Cardiovascular Disease
  • Sleep Duration as a Risk Factor for Cardiovascular Disease – a Review of the Recent Literature
  • The Society for Cardiovascular Angiography and Interventions: Poor sleep has been linked to CVD Biomarkers
  • Hemostatic Alterations in Patients With Obstructive Sleep Apnea and the Implications for Cardiovascular Disease*
  • Elevated C-Reactive Protein in Patients With Obstructive Sleep Apnea
  • SOURCES on Sleep in Science 
  • REFERENCES on Sleep Deprivation, Physiological Processes and Cardiovascular Diseases
Science 18 October 2013:
Vol. 342 no. 6156 pp. 373-377
DOI: 10.1126/science.1241224

Sleep Drives Metabolite Clearance from the Adult Brain

  1. Lulu Xie1,*,
  2. Hongyi Kang1,*,
  3. Qiwu Xu1,
  4. Michael J. Chen1,
  5. Yonghong Liao1,
  6. Meenakshisundaram Thiyagarajan1,
  7. John O’Donnell1,
  8. Daniel J. Christensen1,
  9. Charles Nicholson2,
  10. Jeffrey J. Iliff1,
  11. Takahiro Takano1,
  12. Rashid Deane1,
  13. Maiken Nedergaard1,†

+Author Affiliations


  1. 1Division of Glial Disease and Therapeutics, Center for Translational Neuromedicine, Department of Neurosurgery, University of Rochester Medical Center, Rochester, NY 14642, USA.

  2. 2Department of Neuroscience and Physiology, Langone Medical Center, New York University, New York, NY 10016, USA.
  1. ↵†Corresponding author. E-mail: nedergaard@urmc.rochester.edu
  1. ↵* These authors contributed equally to this work.

The conservation of sleep across all animal species suggests that sleep serves a vital function. We here report that sleep has a critical function in ensuring metabolic homeostasis. Using real-time assessments of tetramethylammonium diffusion and two-photon imaging in live mice, we show that natural sleep or anesthesia are associated with a 60% increase in the interstitial space, resulting in a striking increase in convective exchange of cerebrospinal fluid with interstitial fluid. In turn, convective fluxes of interstitial fluid increased the rate of β-amyloid clearance during sleep. Thus, the restorative function of sleep may be a consequence of the enhanced removal of potentially neurotoxic waste products that accumulate in the awake central nervous system.

 

Figure Source: Goodnight. Sleep Clean.

By MARIA KONNIKOVA JAN. 11, 2014

http://www.nytimes.com/2014/01/12/opinion/sunday/goodnight-sleep-clean.html?emc=eta1&_r=0

Concepts presented in this article about Sleep

  • Maiken Nedergaard, a Danish biologist who has been leading research into sleep function at the University of Rochester’s medical school, told me. “It has to have a basic evolutional function. Otherwise it would have been eliminated.”
  • sleep is essential for forming and consolidating memories and that it plays a central role in the formation of new neuronal connections and the pruning of old ones.
  • Sleep, may play a crucial role in our brain’s physiological maintenance
  • Dr. Nedergaard proposed a brain equivalent of the lymphatic system, a network of channels that cleared out toxins with watery cerebrospinal fluid. She called it the glymphatic system, a nod to its dependence on glial cells (the supportive cells in the brain that work largely to maintain homeostasis and protect neurons) and its function as a sort of parallel lymphatic system.
  • the brain’s interstitial space — the fluid-filled area between tissue cells that takes up about 20 percent of the brain’s total volume — was mainly dedicated to physically removing the cells’ daily waste.
  • When the mouse brain is sleeping or under anesthesia, it’s busy cleaning out the waste that accumulated while it was awake.
  • “We saw almost no inflow of cerebrospinal fluid into the brain when the mice were awake, but then when we anesthetized them, it started flowing. It’s such a big difference I kept being afraid something was wrong,” says Dr. Nedergaard.
  • Not in Humans yet, So far the glymphatic system has been identified as the neural housekeeper in baboons, dogs and goats. “If anything,” Dr. Nedergaard says, “it’s more needed in a bigger brain.”
  • According to the National Sleep Foundation, adults should sleep seven to nine hours. On average, we’re getting one to two hours less sleep a night than we did 50 to 100 years ago and 38 minutes less on weeknights than we did as little as 10 years ago. Between 50 and 70 million people in the United States suffer from some form of chronic sleep disorder.
  • At the University of Pennsylvania’s Center for Sleep and Circadian Neurobiology, Sigrid Veasey has been focusing on precisely how restless nights disturb the brain’s normal metabolism. What happens to our cognitive function when the trash piles up?
  • The faster the fluids clear the decks, the more effectively the brain’s metabolism is functioning.

Consequences of Lack of Sufficient Duration of Sleep

  • the acceleration of neurodegenerative diseases like Alzheimer’s and Parkinson’s. While we don’t know whether sleep loss causes the disease, or the disease itself leads to sleep loss. there is a buildup of the types of proteins that the glymphatic system normally clears out during regular sleep, like beta-amyloids and tau, both associated with Alzheimer’s and other types of dementia.
  • sleep deprivation, as everyone who has experienced it knows, impedes our ability to concentrate, to pay attention to our environment and to analyze information creatively.
  • brains can recover quite readily from short-term sleep loss, chronic prolonged wakefulness and sleep disruption stresses the brain’s metabolism.
  • degeneration of key neurons involved in alertness and proper cortical function and a buildup of proteins associated with aging and neural degeneration.
  • Recovery from sleep loss is slower than we’d thought,” Dr. Veasey notes.
  • mpaired clearance in the awake brain: skipping sleep does irreparable damage to the brain, prematurely aging it or setting it up for heightened vulnerability to other insults.
  • work longer hours, become more stressed, sleep less, impair our brain’s ability to clean up after all that hard work, and become even less able to sleep soundly
  • there’s no evidence that aided sleep is as effective as natural sleep.

New directions for Drug Development

Future drug interventions could focus directly on the glymphatic system, to promote the enhanced cleaning power of the sleeping brain in a brain that is fully awake. One day, scientists might be able to successfully mimic the expansion of the interstitial space that does the mental janitorial work so that we can achieve maximally efficient round-the-clock brain trash pickup.

Curr Probl Cardiol. 2005 Dec;30(12):625-62.

Sleep and cardiovascular disease

Wolk R, Gami AS, Garcia-Touchard A, Somers VK.

Abstract

Sleep is an important modulator of cardiovascular function, both in physiological conditions and in disease states.

In individuals without a primary sleep disorder Sleep may exert significant effects on the

  • autonomic nervous system,
  • systemic hemodynamics,
  • cardiac function,
  • endothelial function, and
  • coagulation.

Some of these influences can be directly linked to specific modulatory effects of sleep stages per se; others result from the natural circadian rhythm of various physiological processes.

There is a temporal association between physiological sleep and

  • occurrence of vascular events,
  • cardiac arrhythmias, and
  • sudden death.

Epidemiological and pathophysiological studies also indicate that there may be a causal link between

  • primary sleep abnormalities (sleep curtailment, shift work, and sleep-disordered breathing) and
  • cardiovascular and metabolic disease, such as hypertension, atherosclerosis, stroke, heart failure, cardiac arrhythmias, sudden death, obesity, and the metabolic syndrome.

Finally, sleep disturbances may occur as a result of several medical conditions (including obesity, chronic heart failure, and menopause) and may therefore contribute to cardiovascular morbidity associated with these conditions. Further understanding of specific pathophysiological pathways linking sleep disorders to cardiovascular disease is important for developing therapeutic strategies and may have important implications for cardiovascular chronotherapeutics.

Sleep Duration as a Risk Factor for Cardiovascular Disease- a Review of the Recent Literature

Curr Cardiol Rev. 2010 February; 6(1): 54–61.
PMCID: PMC2845795
This article has been cited by other articles in PMC.

Abstract

Sleep loss is a common condition in developed countries, with evidence showing that people in Western countries are sleeping on average only 6.8 hour (hr) per night, 1.5 hr less than a century ago. Although the effects of sleep deprivation on our organs have been obscure, recent epidemiological studies have revealed relationships between sleep deprivation and hypertension (HT), coronary heart disease (CHD), and diabetes mellitus (DM). This review article summarizes the literature on these relationships. Because sleep deprivation increases sympathetic nervous system activity, this increased activity serves as a common pathophysiology for HT and DM. Adequate sleep duration may be important for preventing cardiovascular diseases in modern society.

Keywords: Sleep duration, hypertension, coronary heart disease, diabetes mellitus.

The Society for Cardiovascular Angiography and Interventions: Poor sleep has been linked to

  • high blood pressure,
  • atherosclerosis (clogging or hardening of the arteries),
  • heart failure,
  • heart attack,
  • stroke,
  • diabetes, and
  • obesity.

Poor sleep appears to increase substances in your body, such as c-reactive protein, that indicate inflammation is a problem. So, inflammation, which is how the body responds to injury, infection or disease, may be part of the reason poor sleep affects your cardiovascular system. Poor sleep also causes the body to produce more stress hormones, which may contribute to cardiovascular disease.

On the other hand, sometimes symptoms related to cardiovascular disease can be a cause of poor sleep. Angina (chest pain), arrhythmias (abnormal heart rhythms), sleep apnea (a series of breathing pauses during sleep that stress your cardiovascular system), and fluid build-up in the lungs due to heart failure may all disrupt sleep.

The good news is there are steps you can take to improve your sleep. Always talk to your doctor about your sleep problems, however minor you think they might be. There may be lifestyle changes or treatments that can help you sleep better. And read on, so SecondsCount.org can help you improve the quality of sleep you get.

http://www.scai.org/SecondsCount/Treatment/HealthyLiving/SleepandCardiovascularDisease.aspx

Hemostatic Alterations in Patients With Obstructive Sleep Apnea and the Implications for Cardiovascular Disease*

Roland von Känel; Joel E. Dimsdale
Chest. 2003;124(5):1956-1967. doi:10.1378/chest.124.5.1956
Abstract

Study objectives: Patients with obstructive sleep apnea (OSA) are at increased risk for coronary artery and cerebrovascular diseases. Numerous studies suggest that a hypercoagulable state is prospectively related to atherothrombotic events. This review explores whether changes in hemostasis may constitute one biological link between OSA and vascular disease.

Design: Ten studies on hemostatic variables in OSA were located by electronic library search and descriptively reviewed. Work on hemostatic function with physiologic conditions similar to those found in OSA (hypoxemia and hyperactivity of the sympathetic nervous system) was considered to discuss potential molecular mechanisms of procoagulant disturbances in OSA.

Measurements and results: The reviewed data suggest that, as compared to non-OSA control subjects, patients with OSA have elevated plasma fibrinogen levels, exaggerated platelet activity, and reduced fibrinolytic capacity. Although not consistently shown, severity of OSA (ie, apnea-hypopnea index) and plasma epinephrine were independent predictors of platelet activity, and average minimal oxygen saturation was an independent predictor of fibrinogen. In some studies, treatment with continuous positive airway pressure decreased platelet activity, plasma fibrinogen levels, and activity of clotting factor VII.

Conclusions: There is some evidence for a hypercoagulable state in OSA, which might help explain the increased prevalence of vascular diseases in this population. To further confirm such a notion, future studies need to be performed on sufficiently large samples to be able to control for confounders of hemostatic activity. Prospective studies are needed to examine the association between hemostasis molecules and strong vascular end points.

SOURCE

 

Elevated C-Reactive Protein in Patients With Obstructive Sleep Apnea

Circulation.2002; 105: 2462-2464

  1. Abu S.M. Shamsuzzaman, MBBS, PhD;
  2. Mikolaj Winnicki, MD, PhD;
  3. Paola Lanfranchi, MD;
  4. Robert Wolk, MD, PhD;
  5. Tomas Kara, MD;
  6. Valentina Accurso, MD;
  7. Virend K. Somers, MD, PhD

+Author Affiliations


  1. From the Mayo Clinic Rochester, Rochester, Minn.
  1. Correspondence to Virend K Somers, MD, DPhil, Divisions of Hypertension and Cardiovascular Diseases, Mayo Clinic Rochester, 200 First St, SW, Rochester, MN 55905. E-mail somers.virend@mayo.edu

Abstract

Background— Obstructive sleep apnea (OSA) has been increasingly linked to cardiovascular and cerebrovascular disease. Inflammatory processes associated with OSA may contribute to cardiovascular morbidity in these patients. We tested the hypothesis that OSA patients have increased plasma C-reactive protein (CRP).

Methods and Results— We studied 22 patients (18 males and 4 females) with newly diagnosed OSA, who were free of other diseases, had never been treated for OSA, and were taking no medications. We compared CRP measurements in these patients to measurements obtained in 20 control subjects (15 males and 5 females) who were matched for age and body mass index, and in whom occult OSA was excluded. Plasma CRP levels were significantly higher in patients with OSA than in controls (median [range] 0.33 [0.09 to 2.73] versus 0.09 [0.02 to 0.9] mg/dL, P<0.0003). In multivariate analysis, CRP levels were independently associated with OSA severity (F=6.8, P=0.032).

Conclusions— OSA is associated with elevated levels of CRP, a marker of inflammation and of cardiovascular risk. The severity of OSA is proportional to the CRP level.

SOURCE

http://circ.ahajournals.org/content/105/21/2462.short

SOURCES on Sleep in Science

Science 18 October 2013:
Vol. 342 no. 6156 pp. 373-377
DOI: 10.1126/science.1241224
  • REPORT

Sleep Drives Metabolite Clearance from the Adult Brain

 

  1. Lulu Xie1,*,
  2. Hongyi Kang1,*,
  3. Qiwu Xu1,
  4. Michael J. Chen1,
  5. Yonghong Liao1,
  6. Meenakshisundaram Thiyagarajan1,
  7. John O’Donnell1,
  8. Daniel J. Christensen1,
  9. Charles Nicholson2,
  10. Jeffrey J. Iliff1,
  11. Takahiro Takano1,
  12. Rashid Deane1,
  13. Maiken Nedergaard1,†

+Author Affiliations


  1. 1Division of Glial Disease and Therapeutics, Center for Translational Neuromedicine, Department of Neurosurgery, University of Rochester Medical Center, Rochester, NY 14642, USA.

  2. 2Department of Neuroscience and Physiology, Langone Medical Center, New York University, New York, NY 10016, USA.
  1. ↵†Corresponding author. E-mail: nedergaard@urmc.rochester.edu
  1. ↵* These authors contributed equally to this work.

 

The conservation of sleep across all animal species suggests that sleep serves a vital function. We here report that sleep has a critical function in ensuring metabolic homeostasis. Using real-time assessments of tetramethylammonium diffusion and two-photon imaging in live mice, we show that natural sleep or anesthesia are associated with a 60% increase in the interstitial space, resulting in a striking increase in convective exchange of cerebrospinal fluid with interstitial fluid. In turn, convective fluxes of interstitial fluid increased the rate of β-amyloid clearance during sleep. Thus, the restorative function of sleep may be a consequence of the enhanced removal of potentially neurotoxic waste products that accumulate in the awake central nervous system.

  • Received for publication 30 May 2013.
  • Accepted for publication 28 August 2013.

The editors suggest the following Related Resources on Science sites In Science Magazine

In Science Translational Medicine

  • RESEARCH ARTICLE OBESITY AND DIABETES Adverse Metabolic Consequences in Humans of Prolonged Sleep Restriction Combined with Circadian Disruption

    • Orfeu M. Buxton,
    • Sean W. Cain,
    • Shawn P. O’Connor,
    • James H. Porter,
    • Jeanne F. Duffy,
    • Wei Wang,
    • Charles A. Czeisler,
    • and Steven A. Shea

    Sci Transl Med 11 April 2012: 129ra43.

  • RESEARCH ARTICLE SLEEP Uncovering Residual Effects of Chronic Sleep Loss on Human Performance

    • Daniel A. Cohen,
    • Wei Wang,
    • James K. Wyatt,
    • Richard E. Kronauer,
    • Derk-Jan Dijk,
    • Charles A. Czeisler,
    • and Elizabeth B. Klerman

    Sci Transl Med 13 January 2010: 14ra3.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:

  • Taking Out the Garbage During Sleep, and Alzheimer PathologyJournal Watch 2 December 2013: NA32813.
  • Sleep and General Anesthesia Clear the Mouse Brain of Toxic MetabolitesJournal Watch 26 November 2013: NA32960.
  • Cerebral Arterial Pulsation Drives Paravascular CSF-Interstitial Fluid Exchange in the Murine BrainJ. Neurosci. 13 November 2013: 18190-18199.
  • Sleep It Out Science 18 October 2013: 316-317.

SOURCE

REFERENCES on Sleep Deprivation, Physiological Processes and Cardiovascular Diseases
SOURCE
1. Uehata T. Long working hours and occupational stress-related cardiovascular attacks among middle-aged workers in Japan. J Hum Ergol. 1991;20:147–53. [PubMed]
2. National Sleep Foundation. National Sleep Foundation Sleep Survey. Washington, DC: National Sleep Foundation; 2001.
3. Bonnet MH, Arand DL. We are chronically sleep deprived. Sleep. 1995;18:908–11. [PubMed]
4. Webb WB, Agnew HW. Are we chronically sleep deprived? Bull Psychon Soc. 1975;6:47–8.
5. National Sleep Foundation. Sleep in America Poll 2003. Washington, DC: National Sleep Foundation; 2003.
6. Pickering TG. Could hypertension be a consequence of the 24/7 Society? The effects of sleep deprivation and shift work. J Clin Hypertens (Greenwich) 2006:819–22. [PubMed]
7. Wolk R, Shamsuzzaman AS, Somers VK. Obesity, sleep apnea, and hypertension. Hypertension.2003;42:1067–74. [PubMed]
8. Leung RS, Bradley TD. Sleep apnea and cardiovascular disease. Am J Respir Crit Care Med.2001;164:2147–65. [PubMed]
9. Punjabi NM, Polotsky VY. Disorders of glucose metabolism in sleep apnea. J Appl Physiol.2005;99:1998–2007. [PubMed]
10. Wingard DL, Berkman LF. Mortality risk associated sleeping patterns among adults. Sleep.1983;6:102–7. [PubMed]
11. Kripke DF, Simons RN, Garfinkel L, Hammond EC. Short and long sleep and sleeping pills. Arch Gen Psychiatry. 1979;36:103–16. [PubMed]
12. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199–206. [PubMed]
13. National Sleep Foundation. 2002 “Sleep in America” Poll. Washington, DC: National Sleep Foundation; 2002.
14. Gangwisch JE, Heymsfield SB, Boden-Albala B, et al. Short sleep duration as a risk factor for hypertension. Analyses of the First National Health and Nutrition Examination Survey.Hypertension. 2006;47:833–9. [PubMed]
15. Lusardi P, Mugellini A, Preti P, Zoppi A, Derosa G, Fogani R. Effects of a restricted sleep regimen on ambulatory blood pressure monitoring in normotensive subjects. Am J Hypertens. 1996;9:503–5.[PubMed]
16. Lusardi P, Zoppi A, Preti P, Pesce RM, Piazza E, Fogari R. Effects of insufficient sleep on ambulatory blood pressure in hypertensive patients: A 24-h study. Am J Hypertens. 1999;12:63–8.[PubMed]
17. Tochikubo O, Ikeda A, Miyajima E, Ishii M. Effect of insufficient sleep on blood pressure monitored by a new multibiomedical recorder. Hypertension. 1996;27:1318–24. [PubMed]
18. Zhong X, Hilton HJ, Gates GJ, et al. Increased sympathetic and decreased parasympathetic cardiovascular modulation in normal humans with acute sleep deprivation. J Appl Physiol.2005;98:2024–2032. [PubMed]
19. Irwin MR, Valladares EM, Motivala S, Thayer JF, Ehlers CL. Association between nocturnal vagal tone and sleep depth, sleep quality, and fatigue in alcohol dependence. Psychosom Med.2006;68:159–66. [PubMed]
20. Irwin MR, Ziegler M. Sleep deprivation potentiates activation of cardiovascular and catecholamine responses in abstinent alcoholics. Hypertension. 2005;45:252–7. [PubMed]
21. Born J, Lange T, Hansen K, Molle M, Fehm HL. Effects of sleep and circadian rhythm on human circulating immune cells. J Immunol. 1997;158:4454–64. [PubMed]
22. Uthgenannt D, Schoolmann D, Pietrowsky R, Fehm HL, Born J. Effects of sleep on the production of cytokines in humans. Psychosom Med. 1995;57:97–104. [PubMed]
23. Irwin M, Mascovich A, Gillin JC, Willoughby R, Pike J, Smith TL. Partial sleep deprivation reduces natural killer cell activity in humans. Psychosom Med. 1994;56:493–8. [PubMed]
24. Irwin M, McClintick J, Costlow C, Fortner M, White J, Gillin JC. Partial night sleep deprivation reduces natural killer and cellular immune responses in humans. FASEB J. 1996;10:643–53.[PubMed]
25. Irwin M, Thompson J, Miller C, Gillin JC, Ziegler M. Effect of sleep and sleep deprivation on catecholamine and interleukin-2 levels in humans: Clinical implications. J Clin Endocrinol Metab.1999;84:1979–85. [PubMed]
26. Meier-Ewert HK, Ridker PM, Rifai N, et al. Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol. 2004;43:678–83. [PubMed]
27. Folkow B. Mental stress and its importance for cardiovascular disorders; physiological aspects, “from-mice-to-man” Scand Cardiovasc J. 2001;35:163–72. [PubMed]
28. Buell P, Breslow L. Mortality from coronary heart disease in California men who work long hours.J Chorn Dis. 1960;11:615–26. [PubMed]
29. Falger PR, Schouten EGW. Exhaustion, psychological stressors in the work environment, and acute myocardial infarction in adult men. J Psychosom Res. 1992;36:777–86. [PubMed]
30. Netterstrom B, Nielsen FE, Kristensen TS, Bach E, Moller L. Relation between job strain and myocardial infarction: a case control study. Occup Environ Med. 1999;56:339–42. [PMC free article][PubMed]
31. Theorell T, Rahe RH. Behavior and life satisfactions characteristics of Swedish subjects with myocardial infarction. J Chron Dis. 1972;25:139–47. [PubMed]
32. Sokejima S, Kagamimori S. Working hours as a risk factor for acute myocardial infarction in Japan: case-control study. BMJ. 1998;317:775–80. [PMC free article] [PubMed]
33. Partinen M, Putkonen PT, Kaprio J, Koskenvuo M, Hilakivi I. Sleep disorders in relation coronary heart disease. Acta Med Scand. 1982;660(suppl):69–83. [PubMed]
34. Liu Y, Tanaka H. The Fukuoka Heart Study Group. Overtime work, insufficient sleep, and risk of non-fatal acute myocardial infarction in Japanese men. Occup Environ Med. 2002;59:447–51.[PMC free article] [PubMed]
35. Ayas NT, White DP, Manson JE, et al. A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med. 2003;163:205–9. [PubMed]
36. Spiegel K, Leproult R, Van Cauter E. Impact of sleep dept on metabolic and endocrine function.Lancet. 1999;354:1435–39. [PubMed]
37. Spiegel K, Knutson K, Leproult R, Tasali E, Van Cauter E. Sleep loss: a novel risk factor for insulin resistance and type 2 diabetes. J Appl Physiol. 2005;99:2008–19. [PubMed]
38. Gottlieb DJ, Punjabi NM, Newman AB, et al. Association of sleep time with diabetes mellitus and impaired glucose tolerance. Arch Intern Med. 2005;165:863–7. [PubMed]
39. Yaggi HK, Araujo AB, McKinlay JB. Sleep duration as a risk factor for the development of type 2 diabetes. Diabetes Care. 2006;29:657–61. [PubMed]
40. Leproult R, Copinschi G, Buxton O, Van Cauter E. Sleep loss results in and elevation of cortisol levels the next evening. Sleep. 1997;20:865–70. [PubMed]
41. Luboshitzky R, Zabari Z, Shen-Orr Z, Herer P, Lavie P. Disruption of the nocturnal testosterone rhythm by sleep fragmentation in normal men. J Clin Endocrinol Metab. 2001;86:1134–9. [PubMed]
42. Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men: A prospective population based-study. Circulation. 1988;78:539–45. [PubMed]
43. Haffner SM, Karhapaa P, Mykkanen L, Laakso M. Insulin resistance, body fat distribution, and sex hormones in men. Diabetes. 1994;43:212–9. [PubMed]
44. Simon D, Preziosi P, Barrett-Connor E, et al. Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study. Diabetologia. 1992;35:173–7. [PubMed]
45. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts Male Aging Study. Diabetes Care. 2000;23:490–4. [PubMed]
46. Haffner SM, Laakso M, Miettinen H, Mykkanen L, Karhapaa P, Rainwater DL. Low levels of sex hormone-binding globulin and testosterone are smaller, denser low density lipoprotein in normoglycemic men. J Clinic Endocrinol Metab. 1996;81:3697–701. [PubMed]
47. Spiegel K, Tasali E, Penev P, Van Cauter E. Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med. 2004;141:846–50. [PubMed]
48. Reaven GM, Lithell H, Landsberg L. Hypertenison and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374–81.[PubMed]
49. Larsen PJ, Enquist LW, Card JP. Characterization of the multisynaptic neuronal control of the rat pineal gland using viral transneuronal tracing. Eur J Neurosci. 1998;10:128–45. [PubMed]
50. Teclemariam-Mesbah R, Kalsbeek A, Buijs RM, Pevet P. Oxytocin innervation of spinal preganglionic neurons projecting to the superior cervical ganglion in the rat. Cell Tissue Res.1997;287:481–6. [PubMed]
51. Teclemariam-Mesbah R, Ter Horst GJ, Postema F, Wortel J, Bujis RM. Anatomical demonstration of the suprachiasmatic nucleus-pineal pathway. J Comp Neurol. 1999;406:171–82.[PubMed]
52. Kalsbeek A, Drijfhout WJ, Westerink BH, et al. GABA receptors in the region of the dorsomedial hypothalamus of rats are implicated in the control of melatonin and corticosterone release.Neuroendocrinology. 1996;63:69–78. [PubMed]
53. Kalsbeek A, Garidou ML, Palm IF, et al. Melatonin sees the light: blocking GABA-ergic transmission in the paraventricular nucleus induces daytime secretion of melatonin. Eur J Neurosci.2000;12:3146–54. [PubMed]
54. Cui LN, Coderre E, Renaud LP. Glutamate and GABA mediate suprachiasmatic nucleus inputs to spinal-projecting paraventricular neurons. Am J Physiol Regul Integr Comp Physiol.2001;281:R1283–9. [PubMed]
55. Gerendai I, Toth IE, Boldogkoi Z, Medveczky I, Halasz B. CNS structures presumably involved in vagal control of ovarian function. J Auton Nerv System. 2000;80:40–5. [PubMed]
56. La Fleur SE, Kalsbeek A, Wortel J, Buijs RM. Polysynaptic neural pathways between the hypothalamus, including the suprachiasmatic nucleus, and the liver. Brain Res. 2000;871:50–6.[PubMed]
57. Buijs RM, Chun SJ, Niijima A, Romijn HJ, Nagai K. Parasympathetic and sympathetic control of the pancreas: a role for the suprachiasmatic nucleus and other hypothalamic centers that are involved in the regulation of food intake. J Comp Neurol. 2001;431:405–23. [PubMed]
58. Kreier F, Fliers E, Voshol PJ, et al. Selective parasympathetic innervation of subcutaneous and intra-abdominal fat – functional implications. J Clin Invest. 2002;110:1243–50. [PMC free article][PubMed]
59. Nagai K, Nagai N, Shimizu K, Chun S, Nakagawa H, Niijima A. SCN output drives the autonomic nervous system: with special reference to the autonomic function related to the regulation of glucose metabolism. Prog Brain Res. 1996;111:253–72. [PubMed]
60. Kalsbeek A, Strubbe JH. Circadian control of insulin secretion and glucose homeostasis is independent of the temporal distribution of feeding. Physiol Behav. 1998;63:553–8. [PubMed]
61. La Fleur SE, Kalsbeek A, Wortel J, Fekkes ML, Buijs RM. A daily rhythm in glucose tolerance: a role for the suprachiasmatic nucleus. Diabetes. 2001;50:1237–43. [PubMed]
62. Pickering TG. The clinical significance of diurnal blood pressure variations. Dippers and nondippers. Circulation. 1990;81:700–2. [PubMed]
63. Yamamoto M, Yamasaki Y, Kodama M, et al. Impaired diurnal cardiac autonomic function in subjects with type 2 diabetes. Diabetes Care. 1999;22:2072–7. [PubMed]
64. Goncharuk VD, van Heerikhuize J, Dai JP, Swaab DF, Buijs RM. Neuropeptide changes in the suprachiasmatic nucleus in primary hypertension indicate functional impairment of the biological clock. J Comp Neurol. 2001;431:320–30. [PubMed]
65. Borghi C, Costa FV, Boschi S, Mussi A, Ambrosioni E. Predictors of stable hypertension in young borderline subjects: a five-year follow-up study. J Cardiovas Pharmacol. 1986;8(Suppl 5):S138–41.[PubMed]
66. Eilam R, Malach R, Bergmann F, Segal M. Hypertension induced by hypothalamic transplantation from genetically hypertensive to normotensive rats. J Neurosci. 1991;11:401–11.[PubMed]
67. Dunning BE, Ahren B, Veith RC, Taborsky GJ., Jr Noradrenergic sympathetic neural influence on basal pancreatic hormone secretion. Am J Physiol. 1988;255:E785–92. [PubMed]
68. Scheer FA, Van Montfrans GA, van Someren EJ, Mairuhu G, Buijs RM. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension.2004;43:192–7. [PubMed]
69. Cagnacci A, Cannoletta M, Renzi A, Baldassari F, Arangino S, Volpe A. Prolonged melatonin administration decreases nocturnal blood pressure in women. Am J Hypertens. 2005;18:1614–8.[PubMed]
70. Grossman E, Laudon M, Yalcin R, et al. Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am J Med. 2006;119:898–902. [PubMed]
71. Simko F, Paulis L. Melatonin as a potential antihypertensive treatment. J Pineal Res.2007;42:319–22. [PubMed]

Read Full Post »

UPDATED on 2/25/2019
https://www.medpagetoday.com/cardiology/prevention/78202?xid=nl_mpt_SRCardiology_2019-02-25&eun=g99985d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=CardioUpdate_022519&utm_term=NL_Spec_Cardiology_Update_Active

Most paroxysmal atrial fibrillation episodes are triggered by avoidable things, like alcohol, caffeine, or exercise, according to a survey of symptomatic patients published in HeartRhythm.

Air Pollution, Noise and Smoke: Effects on Heart Failure and Other Cardiovascular Diseases

Curator: Aviva Lev-Ari, PhD, RN

 

Study from IUF Leibniz Research Institute for Environmental Medicine: Air and noise pollution may increase risk of cardiovascular disease

Published on May 21, 2013 at 9:34 AM 

Both fine-particle air pollution and noise pollution may increase a person’s risk of developing cardiovascular disease, according to German researchers who have conducted a large population study, in which both factors were considered simultaneously.

“Many studies have looked at air pollution, while others have looked at noise pollution,” said study leader Barbara Hoffmann, MD, MPH, a professor of environmental epidemiology at the IUF Leibniz Research Institute for Environmental Medicine in Germany. “This study looked at both at the same time and found that each form of pollution was independently associated with subclinical atherosclerosis.”

The research was presented at ATS 2013.

“This study is important because it says that both air pollution and noise pollution represent important health problems,” said Dr. Philip Harber, a professor of public health at the University of Arizona who was not involved in the research. “In the past, some air pollution studies have been dismissed because critics said it was probably the noise pollution that caused the harm, and vice versa. Now we know that people who live near highways, for instance, are being harmed by air pollution and by noise pollution.”

Using data from the Heinz Nixdorf Recall study, an ongoing population study from three neighboring cities in the Ruhr region of Germany, Dr. Hoffmann and her colleagues assessed the long-term exposure to fine particulate matter with an aerodynamic diameter <2.5 µm (PM2.5) and long-term exposure to traffic noise in 4238 study participants (mean age 60 years, 49.9% male).

The exposure to air pollutants was calculated using the EURopean Air Pollution Disperson, or EURAD, model. Exposure to traffic noise was calculated using European Union models of outdoor traffic noise levels. These levels were quantified as weighted 24-hour mean exposure (Lden) and nighttime exposure (Lnight).

To determine the association of the two variables with cardiovascular risk, the researchers looked at thoracic aortic calcification (TAC), a measure of subclinical atherosclerosis.

TAC was quantified using non-contrast enhanced electron beam computed tomography. Using multiple linear regression, the researchers controlled for other cardiovascular risk factors, including age, gender, education, unemployment, smoking status and history, exposure to second-hand smoke, physical activity, alcohol use and body mass index.

After controlling for these variables, the researchers found that fine-particle air pollution was associated with an increase in TAC burden by 19.9 % (95%CI 8.2; 32.8%) per 2.4µg/m3. (To put that increase in perspective: in the United States, the Environmental Protection Agency recently revised the overall limit downward from 15 to 12µg/m 3).

The researchers also found that nighttime traffic noise pollution increased TAC burden by 8% (95% CI 0.8; 8.9%) per 5 dB. (An average living room would typically have a noise level of about 40 A-weighted decibels, or dB(A), an expression of the relative loudness of sounds as perceived by the human ear, while busy road traffic would generate about 70-80dB(A)). Mean exposure to traffic noise over 24 hours was not associated with increased TAC.

Among subgroups of participants, the researchers found even stronger associations. The interaction of PM2.5 and TAC was clearer among those younger than 65, participants with prevalent coronary artery disease and those taking statins. In contrast, the effect of Lnight was stronger in participants who were not obese, did not have coronary artery disease and did not take statins.

Although the cross-sectional design of this study limits the causal interpretation of the data, Dr. Hoffmann said, “both exposures seem to be important and both must be considered on a population level, rather than focusing on just one hazard.”

She added that her research group plans to conduct a longitudinal analysis with repeated measures of TAC over time.

SOURCE

http://www.news-medical.net/news/20130521/Study-Air-and-noise-pollution-may-increase-risk-of-cardiovascular-disease.aspx

Air Pollutants Up Heart-Failure Deaths, Hospitalizations, Costs

July 09, 2013

LONDON, UK — Modest reductions in air pollution could prevent almost 8000 hospitalizations for heart failure and save hundreds of millions of healthcare dollars in the US alone, authors of a new study estimate [1] .

Dr Anoop SV Shah and colleagues (University of Edinburgh, Scotland) combined data from 35 studies addressing the health effects of air pollution that included heart-failure end points. In all, data from 12 countries were included in their review, published online today in the Lancet.

They found that of the common airborne pollutants, carbon monoxide was the most frequently studied and was associated with the largest increase in heart-failure hospitalizations or death, although all “gaseous and particulate air pollutants” (with the exception of ozone) were associated with increased HF hospitalization or HF mortality.

HF hospitalization or mortality was increased by 3.52% for every 1-ppm increase in carbon monoxide. For sulfur dioxide and nitrogen dioxide, the corresponding increase in risk was 2.36% and 1.70%, respectively, for every 10-ppb increase. For every 10-µg/m 3-increase in particulate matter, HF hospitalizations or mortality was increased by 2%.

Of note, hospitalizations and deaths from HF peaked at times when air quality was the worst, Shaw and colleagues observed.

Saving Lives and Money

Responding to questions from heart wire , study coauthor Dr David McAllister (University of Edinburgh) stressed that he and his colleagues are not advising patients or clinicians to alter treatments or behavior as a result of the findings.

“The risk to an individual is small, but we are all exposed to air pollution and the effect on the population is important,” he said in an email. “Clinicians can have a powerful voice on behalf of their patients advocating for public policies that reduce air pollution, thereby preventing admission to the hospital and early death for some patients with heart failure.”

“There have been no previous systematic reviews of the effects of air pollution on heart-failure hospitalization,” McAllister noted, and “relatively few studies in patients with heart failure. This is perhaps surprising given the prevalence of heart failure has been inexorably rising due to an aging population and the improved treatment of myocardial infarction. In the United States, the prevalence of heart failure is currently 2% and is expected to rise by 25% by 2013, and there were 4.2 million emergency-department attendances in 2010 for chronic heart failure, with total healthcare costs of $32 billion.”

“All studies except one were done in developed countries where even modest improvements in air-quality standards are projected to have major population health benefits and substantial healthcare cost savings,” Shah et al write. By their estimate, a reduction in small-particle (<2.5 µm) pollutants of just 3.9 µg/m 3 would “save a third of a billion US dollars a year” and prevent 7973 HF hospitalizations.

“Although the causality and biological mechanisms need further exploration, air pollution is a pervasive public-health issue with major cardiovascular and healthcare economic consequences presenting a key target for national and international intervention.”

Setting Limits, Understanding Impact

In an accompanying editorial [2] , Drs Francesco Forastiere and Nera Agabiti (Lazio Regional Health Service, Rome, Italy) point out that the European Union designated 2013 the “Year of Air,” yet the current limit, averaged annually, for fine particulate matter is 25 µg/m 3. This, they note, is substantially higher than the target set by the WHO at 10 µg/m 3, and clearly “adverse health effects of air pollution are present even at concentrations well below this limit.”

In the cities Shah et al’s analysis, the median concentration of particulate matter <2.5 µg was 15 µg/m3, but the authors note that daily fine-particulate-matter concentrations in cities with over 10 million people (eg, New Delhi and Beijing) are estimated at 100 to 300 µg/m 3.

Previous studies of air pollution and cardiovascular events have focused primarily on myocardial infarction and atherosclerosis.

A second paper appearing in the Lancet today shows that even very low levels of air pollution increase the risk of lung cancer [3]. In that analysis, Dr Ole Raaschou-Nielsen (Danish Cancer Society Research Center, Copenhagen) and colleagues show that the risk of lung cancer rose by 18% with every 5-µg/m 3increase in pollution by particulate matter <2.5 µg and even higher with larger-particulate pollution.

Although the increases associated with heart-failure deaths and hospitalizations “are somewhat smaller than for lung cancer, heart failure is considerably commoner than lung cancer, and so the impact on heart failure across the population is nonetheless very important,” McAllister pointed out. “In other words, while the effect on individuals may be small, for populations as a whole the effect of air pollution is considerable.”

The authors for both papers and accompanying editorial declared having no conflicts of interest.

 
 REFERENCES
  1. Shah ASV, Langrish JP, Nair H, et al. Global association of air pollution and heart failure: A systematic review and meta-analysis. Lancet 2013; DOI:10.1016/S0140-6736(13)60898-3. Available at: http://www.thelancet.com.
  2. Forastiere F, Agabiti N. Assessing the link between air pollution and heart failure. Lancet 2013; DOI:10.1016/S0140-6736(13)61167-8. Available at: http://www.thelancet.com.
  3. Raaschou-Nielsen O, Andersen ZJ, Beele R, et al. Air pollution and lung cancer incidence in 17 European cohorts: Prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). Lancet 2013; DOI:10.1016/S1470-2045(13)70279-1. Available at: http://www.thelancet.com.

SOURCE

The most recent study in Europe concluded that:

Long-term Air Pollution Ups Risk of CVD: European Study

Marlene Busko

January 27, 2014

ROME, ITALY — A large meta-analysis of 11 cohorts in five European countries suggests that long-term exposure to air pollution is a cardiovascular risk factor and current standards for air quality in Europe are not strict enough [1] .

Individuals who lived in an area where they breathed in large concentrations of particles of polluted air over a long period had a greater risk of having a first acute coronary event (MI or unstable angina).

This association was seen even when the number of fine particles in the air was below the current European threshold for acceptable air quality.

The findings, from the European Study of Cohorts for Air Pollution Effects (ESCAPE), were published online January 21, 2014 in BMJ.

“Our study suggests an association between long-term exposure to particulate matter and incidence of coronary events,” the researchers, with lead author Giulia Cesaroni(Lazio Regional Health Service, Rome, Italy), write. “The results of this study, together with other ESCAPE findings, support lowering of European limits for particulate air pollution to adequately protect public health,” they conclude.

According to the recent report on the Global Burden of Disease, particulate air pollution is estimated to cause 3.1 million deaths each year worldwide, but the effect of air pollution on the incidence of acute MI and unstable angina was unclear, the authors write.

In the European Union, the current annual limit for fine particulate matter with a diameter of <2.5 µm (PM 2.5) is 25 µg/m 3, which is more than twice as high as the acceptable level in the US, at 12 µg/m 3.

The researchers sought to estimate the association between long-term exposure to air pollution—fine particles, coarse particles, soot, and nitrogen oxide—and the subsequent incidence of acute coronary events.

ESCAPE included 100 166 participants who were enrolled in cohorts in Finland, Sweden, Denmark, Germany, and Italy from 1997 to 2007 and had no previous coronary events at baseline.

During a mean follow-up of 11.5 years, 5157 participants had an incident acute coronary event.

In statistical models that adjusted for age, sex, year of enrollment, smoking, and socioeconomic factors, the researchers found that a 5-µg/m 3 increase in annual exposure to fine (PM 2.5) particulate matter was associated with a 13% increased risk of coronary events, and a 10-µg/m 3 increase in annual exposure to coarse (PM 10) particulate matter was associated with a 12% increased risk of coronary events.

In an accompanying editorial [2] , Drs Michael Brauer and John Mancini (University of British Columbia, Vancouver) note that the study showed that, “significant effects [on cardiac events] were also discernible for exposure levels only slightly above the 10-µg/m 3 World Health Organization [WHO] air-quality guideline” for fine particles, and nearly 90% of the world’s population is exposed to levels of air pollution that exceed this recommended maximum threshold. For example, a recent study showed that in Beijing, levels of fine particles in the air were more than 10 times as high as this over a five-year period [3] .

Brauer and Mancini call for more efforts to reduce other known cardiovascular risk factors, such as smoking, in highly polluted areas. In addition, “people with or at risk of cardiovascular disease who live in highly polluted areas might warrant more aggressive use of primary and secondary preventive therapies, including antiplatelet agents, lipid-lowering agents, and treatments for hypertension or diabetes, all known to prevent cardiovascular events,” they write.

The original studies in the meta-analysis received funding from the European Community’s Seventh Framework Program. The authors have reported they have no conflicts of interest. The editorialists have reported they have no relevant financial relationships.

REFERENCES

  1. Cesaroni G, Forastiere F, Stafoggia M, et al. Long term exposure to ambient air pollution and incidence of acute coronary events: Prospective cohort study and meta-analysis in 11 European cohorts from the ESCAPE Project.BMJ 2014: DOI:10.1136/bmj.f7412. Article
  2. Brauer M and Mancini GBJ. Where there’s smoke . . . BMJ 2014; DOI:10.1136/bmj.g40. Editorial
  3. Guo Y, Li S, Tian Z, et al. The burden of air pollution on years of life lost in Beijing, China, 2004–08: Retrospective regression analysis of daily deaths. BMJ 2013; 347:f7139. Article

SOURCE

Environ Health Perspect. 2007 November; 115(11): A536–A537.
PMCID: PMC2072857
Environews
Forum 

Noise Pollution: The Sound Behind Heart Effects

More than 15 million Americans currently have some form of coronary heart disease (CHD), which involves a narrowing of the small blood vessels that supply blood and oxygen to the heart. Risk factors for CHD include diabetes, high blood pressure, altered blood lipids, obesity, smoking, menopause, and inactivity. To this list we can now add noise, thanks to a recent study and assessment of the evidence by the WHO Noise Environmental Burden on Disease working group. The findings, first presented at the Internoise 2007 conference in August 2007, will be published in December.

“The new data indicate that noise pollution is causing more deaths from heart disease than was previously thought,” says working group member Deepak Prasher, a professor of audiology at University College in London—perhaps hundreds of thousands around the world. “Until now, the burden of disease related to the general population’s exposure to environmental noise has rarely been estimated in nonoccupational settings at the international level.”

The separate noise-related working group first convened in 2003 and began sifting through data from studies in European countries to derive preliminary estimates of the impact of noise on the entire population of Europe. They then sought to separate the noise-related health effects from those of traffic-related air pollution and other confounding factors such as physical inactivity and smoking. In 2007, the group published Quantifying Burden of Disease from Environmental Noise, their preliminary findings on the health-related effects of noise for Europeans. Their conclusion: about 2% of Europeans suffer severely disturbed sleep, and 15% suffer severe annoyance due to environmental noise, defined as community noise emitted from sources such as road traffic, trains, and aircraft.

According to the new figures, long-term exposure to traffic noise may account for approximately 3% of CHD deaths (or about 210,000 deaths) in Europe each year. To obtain the new estimates, the working group compared households with abnormally high noise exposure with those with quieter homes. They also reviewed epidemiologic data on heart disease and hypertension, and then integrated these data into maps showing European cities with different levels of environmental noise.

The noise threshold for cardiovascular problems was determined to be a chronic nighttime exposure of at least 50 A-weighted decibels, the noise level of light traffic. Daytime noise exposures also correlated with health problems, but the risk tended to increase during the nighttime hours. “Many people become habituated to noise over time,” says Prasher. “The biological effects are imperceptible, so that even as you become accustomed to the noise, adverse physiological changes are nevertheless taking place, with potentially serious consequences to human health.”

To further assess the noise-related disease burden, the working group estimated disability-adjusted life years (DALYs) due to noise-related CHD. DALYs reflect how much the expectancy of healthy life is reduced by premature death or by disability caused by disease. This measure lets policy makers compare disease burdens associated with different environmental factors and forecast the likely impact of preventive policies. The working group estimated that in 2002 Europeans lost 880,000 DALYs to CHD related to road traffic noise.

Chronic high levels of stress hormones such as cortisol, adrenaline, and noradrenaline can lead to hypertension, stroke, heart failure, and immune problems. According to a review of the research in the January–March 2004 issue of Noise and Health, arousal associated with nighttime noise exposure increased blood and saliva concentrations of these hormones even during sleep. “Taken together, recent epidemiologic data show us that noise is a major stressor that can influence health through the endocrine, immune, and cardiovascular systems,” says Prasher.

Other recent support for an association of cardiovascular mortality with noise comes from a study published in the 1 January 2007 issue of Science of the Total Environment. The results showed an 80% increased risk of cardiovascular mortality for women who judged themselves to be sensitive to noise. “Given these findings, noise sensitivity is a serious candidate to be a novel risk factor for cardiovascular mortality in women,” says Marja Heinonen-Guzejev, a research scientist at the University of Helsinki and lead author of the paper.

There is also a potential interaction between noise and air pollution, given that individuals exposed to traffic noise, for example, are often simultaneously exposed to air pollution. Prasher is currently investigating the effects of noise alone and in combination with chemical pollution.

The broader implications of chronic noise exposure also need to be considered. “Noise pollution contributes not only to cardiovascular disease, but also to hearing loss, sleep disruption, social handicaps, diminished productivity, impaired teaching and learning, absenteeism, increased drug use, and accidents,” says physician Louis Hagler, who coauthored a review on noise pollution in the March 2007 Southern Medical Journal. “The public health repercussions of increasing noise pollution for future generations could be immense.”

SOURCE

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2072857/

Chronic airplane noise linked to increased risk of cardiovascular disease

By Susan Perry | 10/09/13
REUTERS/Jonathan Ernst
The new studies investigated the relationship between airplane noise and the incidence of cardiovascular disease, not just the incidence of high blood pressure.

Chronic exposure to high levels of airplane noise is associated with an increased risk of developing cardiovascular disease, particularly for older people, according to two new studies published online Tuesday in the journal BMJ.

For one of the studies, researchers examined data on airplane noise and hospital admissions around London Heathrow Airport. For the other, a separate team of researchers pooled and analyzed similar data for multiple U.S. airports.

The Minneapolis-St. Paul International Airport is included in that second study. These findings, therefore, are likely to fuel the controversy surrounding the Metropolitan Airport Commission’s plans to concentrate air traffic over particular neighborhoods of Southwest Minneapolis, Edina and Richfield.

Past research

Previous studies have found an association between airplane noise and an increased risk of sleep problems, anxiety and high blood pressure. But most of that research focused on only a small number of airports or didn’t have sufficient statistical power to strongly support their results. These two new studies are better powered, statistically speaking, than the earlier ones. They also do a better job of adjusting for confounding factors, such as air pollution.

Most important, the new studies investigated the relationship between airplane noise and the incidence of cardiovascular disease, not just the incidence of high blood pressure.

Neither study proves that airplane noise causes heart disease, however. These areobservational studies. They can show only a correlation, not a cause-and-effect relationship, between two things (in this case, airplane noise and heart disease). Other factors, not yet identified and measured, might very well explain both studies’ findings.

The U.S. study

In the larger of the two studies, researchers from Harvard University and Boston University examined 2009 data for more than 6 million Medicare recipients (aged 65 years or older) living near 89 U.S. airports. First, they matched hospitalizations records for cardiovascular illnesses (such as heart failure, stroke, peripheral vascular disease and heart-rhythm disturbances) with the patients’ ZIP codes. Next, with the aid of Federal Aviation Administration data, they determined the airplane-related noise levels of each zipcode.

The researchers then looked to see if there was a relationship between level of noise and the hospitalizations.

“In our analysis, we found that even when controlling for air pollution, proximity to roadways, individual demographics and socioeconomic status, a 10 decimal increase in noise was associated with a 3.5 percent increase in cardiovascular hospital admissions — and this was statistically significant,” said Jonathan Levy, one of the study’s co-authors and a professor of environmental health at Boston University, in a video released with the study.

The analysis also revealed that the strongest association with cardiovascular-disease hospitalizations occurred among the participants exposed to the highest noise levels (more than 55 decibels). (According to the National Institutes of Health, 55 decibels is about the sound of a normal conversation.)

Overall, said Levy, “about 2.3 percent of the cardiovascular hospital admissions were associated with aircraft noise.”

The U.K. study

In the second study, a team of British researchers compared airplane noise with cardiovascular-related hospital admissions among 3.6 million people living near London Heathrow Airport, one of the busiest airports in the world.

They found that people living in the areas around Heathrow with the most airplane noise (63 decibels in the daytime or more than 55 decibels at night) were 20 to 30 percent more likely to be hospitalized for stroke and heart disease than those living in areas with the lowest levels of noise.

The findings remained significant even after adjusting for income levels, ethnicity, smoking (estimated through lung cancer mortality), air pollution and exposure to road-traffic noise.

The researchers were not able, however, to distinguish between daytime and nighttime airplane noise. They called for more studies to help determine if the correlation between airplane noise and heart disease could be the result of sleep disruption.

Important implications

Although both studies may have found an association between high levels of airplane noise and an increased risk of cardiovascular illness, the increased risk is much smaller than that from other established risk factors, such as smoking, high blood pressure, diabetes and obesity.

But that doesn’t mean that the effects of airplane and other environmental noises on human health are negligible.

“Environmental noise is an understudied environmental pollutant that has important implications for public health and policy,” writes Dr. Stephen Stansfeld, a professor of psychiatry at the Queen Mary University of London, in a BMJ commentary that accompanies the published studies.

“These studies,” he adds, “provide preliminary evidence that aircraft noise exposure is not just a cause of annoyance, sleep disturbance, and reduced quality of life but may also increase morbidity and mortality from cardiovascular disease. The results imply that the siting of airports and consequent exposure to aircraft noise may have direct effects on the health of the surrounding population. Planners need to take this into account when expanding airports in heavily populated areas or planning new airports.”

SOURCES

http://www.minnpost.com/second-opinion/2013/10/chronic-airplane-noise-linked-increased-risk-cardiovascular-disease

http://www.psr.org/assets/pdfs/air-pollution-effects-cardiovascular.pdf

Read Full Post »

Calcium and Cardiovascular Diseases: A Series of Twelve Articles in Advanced Cardiology

Curator: Aviva Lev-Ari, PhD, RN

UPDATED on 7/18/2021

ER

IMAGE SOURCE:

Claudio A. Hetz. Antioxidants & Redox Signaling.Dec 2007.

2345-2356. http://doi.org/10.1089/ars.2007.1793

FIG. 3. Regulation of ER calcium homeostasis by the BCL-2 protein family. Different anti- and proapoptotic members of the BCL-2 family of proteins are located at the ER membrane, where they have an important role regulating ER calcium content. BCL-2 and BCL-XL interact with the IP3R calcium channel, modulating its activity. BCL-2 has been shown to increase ER calcium leak through the IP3R because of an increase on its phosphorylation levels.

BAX and BAK have the opposite effect on ER calcium content, a function that may be further modulated by BH3-only proteins (such as PUMA and BIK). In addition, the activity of BCL-2 at the ER membrane is regulated by phosphorylation. JNK phosphorylates BCL-2, decreasing its antiapoptotic activity and increasing ER calcium content, whereas the phosphatase PP2A decreases this phosphorylation through a direct interaction. Alternatively, ER stress activates the IRE1/JNK pathway that may alter the activity of BCL-2 at the ER membrane. BI-1 is also located at the ER membrane, where it regulates calcium homeostasis.

CONCLUSIONS AND THERAPEUTIC PERSPECTIVES

I have summarized different pieces of evidence suggesting that the BCL-2 family of proteins has evolved to regulate multiple processes involved in cell survival under stress conditions. The global view of the current state of the field indicates that the BCL-2–related proteins are not only the “death gateway” keeper (as upstream regulators of caspases), but they also have multiple functions in essential processes for the cell. BCL-2–related proteins are particularly important in the physiologic maintenance of the ER, where they operate as

(a) a calcium rheostat,

(b) modulators of the UPR,

(c) regulators of ER network structure, and

(d) regulators of autophagy.

In addition, examples of a role of the BCL-2 family of proteins in cell-cycle regulation (87, 113), DNA damage responses (37, 114), and glucose/energy metabolism (16) are available, strongly supporting the notion that the BCL-2 protein family is a multifunctional group of proteins that, under normal conditions, participate in essential cellular process. In doing so, the BCL-2 protein family may represent specialized stress sentinels that actively participate in essential processes, allowing a constant homeostatic “quality control.” In response to irreversible cellular damage, particular BCL-2 family members may turn into direct activators of apoptosis.

Mutations in specific genes are responsible for a variety of neurologic disorders due to the misfolding and accumulation of abnormal protein aggregates in the brain. In many of these diseases, it has been suggested that alteration in the homeostasis of the ER contributes significantly to neuronal dysfunction.

These diseases include Parkinson’s disease (32, 84), Alzheimer’s disease (22), prion diseases (27, 28, 31), amyotrophic lateral sclerosis (ALS) (97), Huntington’s disease (63, 90) and many others (see list of diseases in 86). Consequently, the first steps in the death pathways downstream of ER stress represent important therapeutic targets. In this line of thinking, pharmacologic manipulation of the activity of the BCL-2 protein family may have beneficial consequences to treat these fatal diseases. Different small molecules and synthetic peptides are currently available with proven therapeutic applications in mouse disease models, including BCL-2 inhibitors (71), BAX channel inhibitors (29), BAX/BAK activator peptides (100, 101) and many others (see reviews in 52, 79). These drugs may be used as pharmacologic tools to manipulate the activity of stress-signaling pathways regulated by the BCL-2 protein family (i.e., autophagy, calcium metabolism, or the UPR) and their possible role in pathologic conditions.

SOURCE

Claudio A. Hetz.Antioxidants & Redox Signaling.Dec 2007.

2345-2356. http://doi.org/10.1089/ars.2007.1793

  • Published in Volume: 9 Issue 12: November 2, 2007
  • Online Ahead of Print: September 13, 2007

UPDATED on 7/1/2015

We add the following to this series:

Part XIII 

Ca2+-Stimulated Exocytosis:  The Role of Calmodulin and Protein Kinase C in Ca2+ Regulation of Hormone and Neurotransmitter
Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

Part I:

Identification of Biomarkers that are Related to the Actin Cytoskeleton

Larry H Bernstein, MD, FCAP

Part II:

Role of Calcium, the Actin Skeleton, and Lipid Structures in Signaling and Cell Motility

Larry H. Bernstein, MD, FCAP, Stephen Williams, PhD and Aviva Lev-Ari, PhD, RN

Part III:

Renal Distal Tubular Ca2+ Exchange Mechanism in Health and Disease

Larry H. Bernstein, MD, FCAP, Stephen J. Williams, PhD
 and Aviva Lev-Ari, PhD, RN

Part IV:

The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, ArterialSmooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets

Larry H Bernstein, MD, FCAP, Justin Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN

Part V:

Heart, Vascular Smooth Muscle, Excitation-Contraction Coupling (E-CC), Cytoskeleton, Cellular Dynamics and Ca2 Signaling

Larry H Bernstein, MD, FCAP, Justin Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN

Part VI:

Calcium Cycling (ATPase Pump) in Cardiac Gene Therapy: Inhalable Gene Therapy for Pulmonary Arterial Hypertension and Percutaneous Intra-coronary Artery Infusion for Heart Failure: Contributions by Roger J. Hajjar, MD

Aviva Lev-Ari, PhD, RN

Part VII:

Cardiac Contractility & Myocardium Performance: Ventricular Arrhythmias and Non-ischemic Heart Failure – Therapeutic Implications for Cardiomyocyte Ryanopathy (Calcium Release-related Contractile Dysfunction) and Catecholamine Responses

Justin Pearlman, MD, PhD, FACC, Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

Part VIII

Disruption of Calcium Homeostasis: Cardiomyocytes and Vascular Smooth Muscle Cells: The Cardiac and Cardiovascular Calcium Signaling Mechanism – Part VIII

Justin Pearlman, MD, PhD, FACC, Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

Part IX

Calcium-Channel Blockers, Calcium Release-related Contractile Dysfunction (Ryanopathy) and Calcium as Neurotransmitter Sensor – Part IX

Justin Pearlman, MD, PhD, FACC, Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

Part X

Synaptotagmin functions as a Calcium Sensor: How Calcium Ions Regulate the fusion of vesicles with cell membranes during Neurotransmission – Part X

Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

Part XI

Sensors and Signaling in Oxidative Stress – Part XI

Larry H. Bernstein, MD, FCAP

Part XII

Atherosclerosis Independence: Genetic Polymorphisms of Ion Channels Role in the Pathogenesis of Coronary Microvascular Dysfunction and Myocardial Ischemia (Coronary Artery Disease (CAD)) – Part XII

Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD,

Read Full Post »

Voice from the Cleveland Clinic: On the New Lipid Guidelines and On the ACC/AHA Risk Calculator

Reporter: Aviva Lev-Ari, PhD, RN

Article ID #107: Voices from the Cleveland Clinic: On the New Lipid Guidelines and On the ACC/AHA Risk Calculator. Published on 1/21/2014

WordCloud Image Produced by Adam Tubman

This article covers the following related topics:

I. Voices from Cleveland Clinic: Love ‘Em or Leave ‘Em: Experts on Both Sides Debate the New Lipid Guidelines

http://www.medscape.com/viewarticle/819288?nlid=45683_2562&src=wnl_edit_medp_card&uac=93761AJ&spon=2

II.  JAMA Weighs In on CVD Guidance, Statins in Primary Prevention

http://www.medscape.com/viewarticle/814960

III.  How Good Is the New ACC/AHA Risk Calculator?

http://www.medscape.com/viewarticle/814579

IV.  New Cholesterol Guidelines Abandon LDL Targets

http://www.medscape.com/viewarticle/814152

V. New CV Risk-Assessment Guidance Counts Stroke With CHD Risk

http://www.medscape.com/viewarticle/814206

VI.  NIH Says ATP 4, JNC 8 Guidance Out ‘in a Matter of Months’ (With a Twist)

http://www.medscape.com/viewarticle/806563

VII.  New European Hypertension Guidelines Released: Goal Is Less Than 140 mm Hg for All

http://www.medscape.com/viewarticle/806367

VIII.  New guidelines on primary stroke prevention from AHA/ASA

http://www.medscape.com/viewarticle/790766

IX.  New ACC/AHA/NHLBI Guidance on Lifestyle for CVD Prevention

http://www.medscape.com/viewarticle/814139

X. New Obesity Guidelines: Authoritative ‘Roadmap’ to Treatment

http://www.medscape.com/viewarticle/814202

XI.  USPSTF Updates Adult Obesity-Overweight Screening Guidelines

http://www.medscape.com/viewarticle/766342

Voices from the Cleveland Clinic: On the New Lipid Guidelines and On the ACC/AHA Risk Calculator

Love ‘Em or Leave ‘Em: Experts on Both Sides Debate the New Lipid Guidelines

January 20, 2014

DALLAS, TX and WASHINGTON, DC — It has been two months since the new clinical guidelines for the treatment of cholesterol were published[1], and feedback is starting to slowly emerge as clinicians begin incorporating the recommendations into clinical practice.

The American College of Cardiology (ACC) and American Heart Association (AHA) guidelines, which were developed in conjunction with the National Heart, Lung, and Blood Institute (NHLBI), were a radical departure from previous iterations, most notably in their abandonment of LDL-cholesterol targets. In the past, clinicians were advised to treat patients with cardiovascular disease to less than 100 mg/dL or the optional goal of less than 70 mg/dL.

As reported by heartwire  at the time, the expert panel stated there was simply no evidence from randomized, controlled clinical trials to support treatment to a specific target. As a result, the new guidelines make no recommendations for specific LDL-cholesterol or non-HDL targets for the primary and secondary prevention of atherosclerotic cardiovascular disease.

Dr Stanley Hazen

For one clinician, Dr Stanley Hazen (Cleveland Clinic, OH), the strict adherence to only clinical-trial data is a limitation and not a strength of the new guidelines.

“First, it ignores a wealth of information on the pathophysiology of the disease process. Second, it presumes that the reason trials are designed is to answer guideline questions,” he told heartwire . “They aren’t. Trials are designed by pharmaceutical companies trying to get claims issued on their drugs. More important, the absence of randomized clinical-trial data does not justify inaction if LDL cholesterol remains elevated.”

Accelerating Vascular Age

In his commentary published January 8, 2014 in the Cleveland Clinic Journal of Medicine, Hazen, along with first author Dr Chad Raymond (Cleveland Clinic, OH), lay out their concerns with the clinical guidelines and highlight some of the shortcoming with the new recommendations[2].

For Hazen, there are multiple reasons that physicians should continue to treat to specific LDL-cholesterol targets, the first and foremost being that patients are different and no single treatment fits such a large and heterogeneous patient population at risk for cardiovascular disease and stroke. The guidelines simply call for a moderate- or high-dose statin in high-risk patients depending on the clinical scenario and no subsequent assessment of LDL cholesterol.

“In the very highest-risk patients, the ones with extraordinarily high levels of cholesterol, those who get maximally tolerated statins, if there is still a substantial LDL-cholesterol burden, they are going to have substantial residual risk,” he said. “The preponderance of data in aggregate shows that there is higher residual risk proportionate to the LDL level that’s remaining. The new guidelines completely ignore the pathophysiology of the disease process—a disease that takes decades to develop.”

The clinical guidelines are unique among documents past in that the emphasis is strictly on statin therapy rather than LDL-cholesterol-lowering medications more generally. In individuals with atherosclerotic cardiovascular disease, high-intensity statin therapy—such as rosuvastatin (Crestor, AstraZeneca) 20 to 40 mg or atorvastatin 40 to 80 mg—should be used to achieve at least a 50% reduction in LDL cholesterol unless otherwise contraindicated or when statin-associated adverse events are present. In that case, doctors should use a moderate-intensity statin. Similarly, for those with LDL-cholesterol levels >190 mg/dL, a high-intensity statin should be used with the goal of achieving at least a 50% reduction in LDL-cholesterol levels.

For Hazen, the new clinical guidelines “turn back the clock on cardiovascular disease prevention” and have the potential to both overtreat older low-risk patients and undertreat those who are young yet are at higher lifetime risk.

For example, he cites a 25-year-old man who presents because his 45-year-old father just died from a heart attack. He has a fasting total cholesterol level of 310 mg/dL, HDL cholesterol of 50 mg/dL, triglyceride level of 400 mg/dL, and LDL cholesterol of 180 mg/dL. Even with the strong family history of premature coronary disease, because of his young age, the current guidelines do not suggest treatment because they do not apply to those less than 40 years old. However, even if his age were 40, his calculated 10-year risk would be <7.5% based on a new and controversial risk calculator published alongside the guidelines.

“I can’t imagine there is a lipidology expert or cardiologist out there who would think that this patient does not deserve aggressive preventive efforts and intervention,” said Hazen. “It is lifetime risk and lifetime exposure to higher LDL cholesterol that contributes to the disease process. Ignoring that scientific fact in a document whose focus is on treating cholesterol to prevent cardiovascular disease is simply illogical.”

A Massive Paradigm Shift

Speaking with heartwire , Dr James de Lemos (University of Texas Southwestern Medical Center, Dallas) suspects there remains some hesitancy on the part of practicing primary-care physicians to adopt the guidelines, mainly because they are a “massive paradigm shift that dramatically changes the approach to disease.” He said while there are always early adopters, there have been some questions as to which major journals and cardiology organizations would line up behind them (and nearly all have, with the exception of the American Association of Clinical Endocrinologists ).

For cardiologists, on the other hand, the shift to focus on four specific types of patients is not so dramatic, because these are patients they routinely see in clinical practice. For de Lemos, it is reasonable to focus on at-risk patients and treat according to that level of risk. He still incorporates measuring LDL-cholesterol levels, however, noting that the measurement can provide some reassurance or concern depending on the threshold achieved with treatment, dietary changes, and exercise.

Dr Mariel Jessup

To heartwire , Dr Mariel Jessup (University of Pennsylvania, Philadelphia), the president of the AHA, said that immediately following their publication many of her colleagues began implementing the guidelines and using the new calculator for risk assessment. In doing so, they identified patients on statins who did not require the lipid-lowering drugs as well as patients who weren’t on them but should be.

“In the first week, we were all coming to terms with what contributes to risk,” said Jessup. She added that she hasn’t heard a great deal of criticism about the guidelines and believes most physicians are getting on board with the new changes.

She noted that a member of the Penn faculty recently delivered medical grand rounds on the new lipid guidelines and while it was mostly positive, one criticism that arose was the emphasis on randomized, controlled clinical-trial data. Jessup said that even though the new guidelines focus on clinical-trial data, this does not negate findings from observational or epidemiological studies.

Dr Roger Blumenthal

Dr Roger Blumenthal (Johns Hopkins Ciccarone Preventive Cardiology Center, Baltimore, MD), on the other hand, predicts a return to LDL treatment goals in the not-so-distant future.

“I think the guidelines will revert back to the way they were once we get a positive study showing that adding another agent to a statin reduces risk,” Blumenthal said. He predicts positive results with anacetrapib (Merck, Whitehouse Station, NJ), the novel cholesteryl ester transfer protein (CETP) inhibitor, or one of the investigational proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, when given on top of statins. “When that happens, the new randomized controlled trial data would support going lower than what would be achieved with giving just 40 mg or 80 mg of atorvastatin.”

In very selected patients, Blumenthal still aggressively targets to low LDL levels, even if this requires adding a second agent. For example, in patients treated with a statin, LDL cholesterol might be reduced to 80 mg or so, but triglyceride levels remain high or HDL cholesterol is low. He notes that the ACCORD study with fenofibrate was borderline nonsignificant in patients with low HDL cholesterol and high triglyceride levels. Beyond fibrates, he notes there have been angiographic studies published in support of the “lower-is-better” hypothesis.

Jessup said that most physicians understand why the LDL targets were eliminated, but many institutions used the thresholds as a performance measure. Penn Health, for example, used the number of patients treated to the old LDL-cholesterol targets as an internal marker of performance for physicians in internal medicine and general practice. “As you struggle to come up with an easily defined target that you can use to talk about quality in a large practice, and not just among cardiologists, that’s one less target you can use,” said Jessup.

Concerns Among Clinicians as Well

Dr Rita Redberg

Dr Rita Redberg (University of California, San Francisco) also has significantconcerns about the new guidelines, albeit for entirely different reasons. An outspoken critic when the guidelines were presented, her views have not changed, telling heartwire that she is already looking forward to the next version of the cholesterol guidelines. When they were first published and presented, Redberg, along with Dr John Abramson (Harvard Medical School, Boston, MA), argued that statins were beneficial for individuals with heart disease but do not reduce the risk of death in individuals with a 10-year risk of cardiovascular disease of less than 20%.

“I have not been implementing these guidelines because I don’t think they’re in the best interests of my patients, and I really do look forward to the revisions,” she said. “I’m all for looking at risk, and I’m all for targeting prevention strategies on the basis of risk, so I think this is a strong point of the new guidelines. However, that is really undermined by the risk calculator, in which anybody over age 65 basically needs to be on a statin. I don’t think the data support this.”

The new cholesterol guidelines weathered a rough roll-out their first week when Drs Paul Ridker and Nancy Cook (Brigham and Women’s Hospital, Boston, MA) calculated the 10-year risk of cardiovascular events in three large-scale primary prevention cohorts—the Women’s Health Study(WHS), the Physicians’ Health Study (PHS), and the Women’s Health Initiative Observational Study (WHI-OS)—and found the new algorithm overestimated the risk by 75% to 150%.

Dr James de Lemos

To de Lemos, the controversial aspect of the new guidelines remains in the primary-prevention population. For those without cardiovascular disease but who have LDL-cholesterol levels ranging from 70 mg/dL to 189 mg/dL and a 10-year risk of cardiovascular disease >7.5%, physicians can initiate treatment with a statin. Given the controversy surrounding the risk calculator, there have been suggestions that people who don’t need statins will receive treatment.

“It doesn’t mean the concept is flawed,” de Lemos told heartwire , “but it just might not be ready to implement widely.” As a result, he suspects that physicians might be keeping the risk calculator at arm’s length until it is studied and debated further. As for his own use, de Lemos said he doesn’t calculate 10-year risk in every patient, even though he is fairly aggressive with initiating statin therapy, and that his decisions are more intuitive and empirical, something which he doesn’t see changing.

Jessup said the risk calculator, as well as the clinical guidelines, will be updated as new information emerges. While she was not able to speak to specifics, Jessup is aware of researchers testing the predictive strength of the risk calculator in different cohorts to see how well it performs. In general, she said the calculator performs reasonably well.

Some Docs Finding the Calculator Helpful

Dr Sekar Kathiresan

Dr Sekar Kathiresan (Brigham and Women’s Hospital, Boston, MA), who runs a primary-prevention clinic, does use the new clinical guidelines and the new risk calculator to inform his decisions about whether or not to start patients with a moderate- or high-dose statin. He said Ridker and Cook raise a valid scientific point in terms of how well it is calibrated, but this should be put in perspective, given that physicians for the past 20 years or so have used the Framingham Risk Score, a score derived from a few thousand white individuals from one town in the US. The new risk equation increases the population sampled, includes different ethnicities, and is derived from more than one geographic area.

“Is the pooled-cohort equation perfect?” he asked. “No, it won’t be perfect, because it’s an attempt to estimate risk on a sample of 25 000 people.”

Blumenthal made similar comments, telling heartwire that the risk calculator is a better way to estimate risk in women and African Americans, for example. Given that the risk calculator might overestimate risk, he expands his definition of intermediate risk to include patients with a 5% to 15% 10-year risk of cardiovascular disease. In doing so, even if the risk calculator overestimates by a factor of two, they have some wiggle room in discussing care with the patient.

In addition, Blumenthal said the guidelines emphasize a discussion with the patient about care in those with a 10-year risk exceeding 7.5%, just as would be done with an intermediate-risk patient. The discussion can lead to further refinement of risk by taking family history into account or by performing a computed tomography (CT) scan to assess coronary artery calcium (CAC).

To Kathiresan, moving away from LDL-cholesterol targets will require some time before they become readily accepted, mainly because physicians have gotten used to the targets. For the most part, though, he views the changes to the guidelines as more of a “tweak.”

“I don’t find them as radical as some people do,” Kathiresan told heartwire . “I actually think the major thing that was accomplished was taking the focus away from using medications to change lab tests and to now focus on medication proven to reduce the risk of disease. This is a huge plus for the new guidelines.”

In cardiology, the evidence base is very rich, with many trials and millions of dollars spent to evaluate whether specific medicines work to reduce disease risk in specific clinical situations, he added. This is the evidence that should be used to inform clinical practice. For this reason, he entirely agrees with the new focus on statins and not simply lipid-lowering agents.

“There is an incredible amount of inappropriate use of both niacin and fibrates in the US, all based on the fact that they change lab tests,” said Kathiresan. “The clinical-trial evidence for those two medicines is disappointingly poor.”

Hazen is a coinventor on pending and issued patents held by the Cleveland Clinic relating to cardiovascular diagnostics and therapeutics. He is a paid consultant to the Cleveland Heart Lab, Esperion, Liposciences, Merck, Pfizer, and Procter & Gamble. He has received research funds from Abbott, Astra Zeneca, Cleveland Heart Lab, Esperion, Liposciences, Procter & Gamble, and Takeda. In addition, he is entitled to royalty payments for inventions/discoveries related to cardiovascular diagnostics and therapeutics from Abbott Laboratories, Cleveland Heart Lab, Esperion, Frantz Biomarkers, and Liposciences . 

de Lemos acknowledges grant support from Roche Diagnostics and Abbott Diagnostics and has consulted for Diadexus. 

Kathiresan reports serving as a consultant to Merck, Pfizer, Celera, and Alnylam.

Jessup, Blumenthal, and Redberg report no conflicts of interest.

REFERENCES

  1. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association. J Am Coll Cardiol 2013. Article. Circulation 2013. Article.
  2. Raymond C, Cho L, Rocco M, Hazen SL. New cholesterol guidelines: Worth the wait? Cleve Clin J Med 2014; DOI: 10.3949/ccjm.81a.13161. Article

SOURCE

http://www.medscape.com/viewarticle/819288#1

Read Full Post »

Diet Strategies for Prevention of Hypertension in Japanese vs. Americans: Alcohol Consumption vs. Weight Management

Reporter: Aviva Lev-Ari, PhD, RN

In a new article on a study supported by the Ministry of Health, Labor, and Welfare of Japan; Intramural Research Fund, National Cerebral and Cardiovascular Center; and Ministry of Education, Science, and Culture of Japan, Dr. Kokubo explains the different strategies needed for Prevention of Hypertension in Japanese by decrease of Alcohol Consumption and in Americans by applying Weight Management methods to reduce weight.

Kokubo Y. Prevention of hypertension and cardiovascular diseases: A comparison of lifestyle factors in Westerners and East Asians. Hypertension 2014; DOI:10.1161/HYPERTENSIONAHA.113.00543. Text

http://hyper.ahajournals.org/content/early/2014/01/13/HYPERTENSIONAHA.113.00543.citation

Best Ways to Cut Hypertension Differ for Westerners, Asians

Fran Lowry

January 17, 2014

OSAKA, Japan — A new review should serve as a reminder to physicians that lifestyle modifications are the cornerstone of hypertension prevention, but not all changes work for all populations. Because of differences in genes, diet, and lifestyle, the contributions of blood pressure to stroke are different for Westerners and East Asians, writes Dr Yoshihiro Kokubo (National Cerebral and Cardiovascular Center, Osaka, Japan).

“The guidelines put out by the United States, Europe, China, and Japan for lifestyle modifications for prevention of hypertension are similar,” Yoshihiro writes. “Namely, salt restriction, high consumption of vegetables and fruits, increased intake of fish and reduced content of saturated/total fat, appropriate weight control, regular physical exercise, moderate alcohol consumption, and quitting smoking.”

These factors are also considered important for stroke prevention, Kokubo adds in his review published online January 13, 2014 in Hypertension.

Given how different these populations are, Kokubo decided to compare findings from lifestyle status in Westerners vs East Asians with regard to these hypertension guidelines.

“Even in East Asians, for example, fish consumption is different between Chinese and Japanese,” he told heartwire . “I wanted to review lifestyles according to the lifestyle modifications that appear in different guidelines, because I thought that this would lead to a beginning of improvement of both lifestyle changes and effects on blood pressure.”

Salt Restriction

Many studies have shown that reduced salt intake is directly related to decreased blood pressure, including the Dietary Approaches to Stop Hypertension (DASH), International Study of Salt and Blood Pressure (INTERSALT), and International Study of Macro-Micronutrients and Blood Pressure (INTERMAP).

However, salt intake of Northern Japanese is among the highest in East Asia due to a high consumption of tsukemono (pickled vegetables), soy sauce, and miso soup. Consumption of carbohydrate in the form of rice and lower intakes of saturated fat and animal protein are believed to be the link with an increased risk of intracerebral hemorrhage in this population, Kokubo notes.

Also, Asians have a genetically higher salt sensitivity, and salt sensitivity in general is different among different populations, which indicates that the blood pressure response to sodium varies among ethnic groups.

Because of these factors, East Asians need to have more counseling about salt consumption, Kokubo says.

More of This, Less of That

Other findings of Kokubo’s review include:

  • Westerners consume more meat and saturated fat, and therefore diets that restrict these foods will result in greater benefit regarding blood pressure control and atherosclerotic disease in this population.
  • Japanese, on the other hand, have high fish and soy intake, which may contribute to their having the lowest coronary heart disease mortality in the world.
  • Obesity and overweight are increasing worldwide, but men and women from East Asia are generally less heavy, potentially reducing their risk. However, increased body-mass index in male Japanese office workers has been shown to be a strong risk factor for hypertension.
  • Regular physical exercise is important for reducing hypertension in both Westerners and East Asians.
  • Japanese men have the highest consumption of alcohol, higher than American and British men. On the other hand, Western women consume more alcohol than Asian women. A campaign to reduce alcohol intake among Japanese men may be particularly beneficial in reducing their blood pressure.
  • East Asian men continue to smoke more than Westerners. Smoking rates of 40% to 60% among East Asian men are among the highest in the world. Smoking cessation efforts would have a greater impact in East Asian than Western countries.

Different Strokes for Different Folks

In his conclusion, Kokubo writes that a high consumption of fruits and vegetables, regular physical exercise, and maintaining appropriate body weight are all beneficial for blood pressure control in both Western and East Asian populations.

East Asians have the benefit of diets higher in fruits, vegetables, and fish, and a lower incidence of obesity, but they have a genetically higher salt sensitivity and greater salt intake than Westerners.

Also, excessive alcohol intake contributes to increased blood pressure in Japanese men, which is especially dangerous given their high rate of aldehyde dehydrogenase deficiency, a risk factor for hypertension, Kokubo writes.

By contrast, “Westerners need to pay attention to weight control, including regular exercise, and consider replacing dietary meat high in saturated fat with fish,” he said.

“Further comprehensive prospective studies are anticipated to show how each factor contributes to blood pressure control and a reduced risk of CVD in Westerners and East Asians,” Kokubo concludes.

Kokubo reports no relevant financial relationships. The study was supported by the Ministry of Health, Labor, and Welfare of Japan; Intramural Research Fund, National Cerebral and Cardiovascular Center; and Ministry of Education, Science, and Culture of Japan.

SOURCE

http://www.medscape.com/viewarticle/819392?nlid=45683_2562&src=wnl_edit_medp_card&uac=93761AJ&spon=2

Other related articles published in this Open Access Online Scientific Journal, include the following:

Increased Consumption of Dietary Fiber is associated with a significantly Lower Risk of CVD and CHD
Aviva Lev-Ari, PhD, RN
Multivitamins – Don’t help Extend Life or ward off Heart Disease and Improve state of Memory Loss
Aviva Lev-Ari, PhD, RN
Portion Control as a Strategy in Weight Management to lower the Risk for Cardiovascular Diseases
Aviva Lev-Ari, PhD, RN
American Diet is LOW in four important Nutrients that have a direct bearing on Aging and the Brain
Aviva Lev-Ari, PhD, RN
Daily Sugar Intake: Diet Soft Drinks – Weight Gain and Diabetes
Aviva Lev-Ari, PhD, RN

Read Full Post »

Cardiovascular Risk Reduction in Diabetes in Sub-Saharan Africa

Reporter and Curator: Larry H. Bernstein, MD, FCAP 

 

In the immediate preceding article we discussed the problem of small subsistence farming and dependence on crop, and milk as a main source of food. We discussed the dilemma of unavailability of adequate nutrition, that posed a dilemma.  Insects invade and destroy the vegetation.  That can be avoided by either of two choices, crop-treatment with pesticide or by GMO crops resistant to types of destruction, both having unaffordable costs that impose an austere challenge and abject poverty with marginal after sales gains, in no way comparable to farming in Iowa, Wisconsin, Minnesota, or California, U.S.  So the situation could be improved by the introduction of/or development of a practical genome-based synthetic tehnology that might be free of Western dominance, if there were the home-based universities and scientific research.
I also touched on the consequences of the malnutrition in that region because of a diet that imposes either marasmic or kwashiorkor-like feature, the distinction being made based on the body compartment related to loss of fat mass or the loss of lean body mass, the latter being more serious.

Cardiovascular Risk Reduction in Diabetes in Sub-Saharan Africa

The abstract of this discussion is directly taken from an article published in Clinical Medicine Insights: Cardiology; 2008: 2: 25-31,  Libertas Academica, ISSN(s):1178-1165.  Added to DOAJ: 2008-05-01
http://la-press.com/article.php?article_id=529

Cardiovascular Risk Reduction in Diabetes in Sub-Saharan Africa: What should the Priorities be in the Absence of Global Risk Evaluation Tools?

Subjects: Diseases of the circulatory (Cardiovascular) system, Specialties of internal medicine, Internal medicine, Medicine, Cardiovascular, Medicine (General), Health Sciences
Andre Pascal Kengne, Alfred Kongnyu Njamnshi, Jean Claude Mbanya

Keywords: diabetes mellitus, cardiovascular disease, risk factors, prevention, Sub-Saharan Africa

Background

The growing burden of type 2 diabetes in Sub-Saharan Africa (SSA) and related cardiovascular complications call for vigorous actions into prevention. Comprehensive cardiovascular risk evaluation is important for the success of such actions.

Methods

We have reviewed 3 currently existing sets of recommendations for cardiovascular prevention in diabetes in SSA. Distribution of major risk factors and patterns of reported cardiovascular outcomes are used to suggest orientations for cardiovascular prevention in diabetes in this region. Papers and reports published over the period 1990 to 2007 were used.

Results

Existing guidelines share some similarities, but also have areas of inconsistencies. They are generally adaptations of existing guidelines, focused more on individual risk factors, and are not usually backed-up by local evidence.

  • They all have a projection on blood pressure lowering.

This focus is supported by the high prevalence of hypertension among people with diabetes in SSA.

  • Blood pressure and tobacco smoking are the modifiable risk factors accessible to evaluation and interventions on a wide scale in SSA.

Appropriate blood pressure control will have a major impact on stroke (the commonest cardiovascular disease) through

  • a reduction of the cerebrovascular risk, and
  • to a lesser extent on coronary heart disease and
  • total deaths in diabetes in this region.

Conclusions

In the absence of global risk evaluation tools,

  • the use of blood pressure lowering as a primary focus of cardiovascular prevention strategies is relevant for SSA.

However, there is a need to set-up diabetes and stroke registers

  • to monitor outcomes and generate tools for accurate risk prediction and management in diabetes in this region.

Read Full Post »

Market Impact on Global Suppliers of Renal Denervation Systems by Pivotal US Trial: Metronics’ Symplicity Renal Denervation System FAILURE at Efficacy Endpoint

Curator and Reporter: Aviva Lev-Ari, PhD, RN

UPDATED on 1/16/2025

Momentum continues for renal denervation as CMS considers national Medicare coverage

UPDATED on 12/8/2015

New Approaches to Denervation Therapy — TCT 2015

http://www.dicardiology.com/videos/new-approaches-denervation-therapy-%E2%80%94-tct-2015/4592515437001

UPDATED on 2/22/2014

Cordis Corporation Receives CE Mark for RENLANE Renal Denervation System to Treat Resistant Hypertension

February 21, 2014 09:59 AM Eastern Standard Time

FREMONT, Calif.–(BUSINESS WIRE)–Cordis Corporation announced today that it has received European CE Mark for its RENLANE™ Renal Denervation System for the treatment of patients with resistant hypertension and has completed the first successful cases in Europe. The RENLANE™ System consists of a unique, helical shaped, irrigated, multi-electrode ablation catheter with a multi-channel radiofrequency (RF) ablation system.

“The design of the catheter also makes handling the device very easy.”

The first successful cases were performed by Hannes Reuter, M.D., at the University of Cologne Hospital in Germany. The treated patients were diagnosed with resistant hypertension and had systolic blood pressures greater than or equal to 160 mm Hg, despite undergoing traditional drug therapy with three or more anti-hypertensive medications. All procedures were performed successfully and patients were discharged after one day.

“The novel technological design of the RENLANE™ Renal Denervation Catheter with its configuration of five electrodes and irrigated technology, allows for shorter procedure duration, sparing of contrasting dye and likely more protection of the endothelium,” said Hannes Reuter, M.D., University of Cologne, Germany. “The design of the catheter also makes handling the device very easy.”

Nearly one billion people worldwide live with hypertension, or high blood pressure, and the World Health Organization estimates that it is the cause of one in every eight deaths, making hypertension the third leading cause of death worldwide.1 Chronic high blood pressure is a serious condition that can lead to increased risk of stroke, kidney disease, heart attack and heart failure. It is estimated that between 15 and 30 percent of treated hypertensive patients are resistant to traditional drug therapy, defined as failure to respond to three or more drugs.2 Uncontrolled hypertension is a major risk factor for mortality so alternative therapies such as renal denervation for treatment-resistant patients have emerged to help address this patient population. Additionally, the economic burden of the condition is significant. The International Society of Hypertension estimates the annual cost of healthcare expenditure directly related to elevated blood pressure to be almost $500 billion.3

“Chronic hypertension poses a significant health risk to patients and also places a huge burden on global health care systems,” said Celine Martin, Worldwide President, Cordis Corporation. “We are pleased to make our RENLANE™ Renal Denervation System available to European clinicians in need of solutions for patients who do not respond to traditional drug therapy. And we are looking forward to gaining more experience with this therapy and making it available to more patients in need of treatment around the world.”4

The RENLANE™ Renal Denervation Catheter features five irrigated electrodes located at the tip of the ablation catheter and is used in conjunction with the RENLANE™ Multi-Channel RF generator for energy delivery. It is indicated for use in adult patients (> 18 years) with drug resistant hypertension to denervate the renal arteries to reduce blood pressure.

The RENLANE™ Renal Denervation System is another addition to Cordis’ broad and growing portfolio of minimally invasive therapies for patients that suffer from cardiovascular disease worldwide. The company is committed to working with leading clinicians to address the significant and growing burden of cardiovascular disease with innovative endovascular solutions that address the clinical needs of our customers and the patients they treat.

About Renal Denervation

Renal denervation is a minimally invasive, catheter-based treatment for resistant hypertension, or high blood pressure that does not respond to traditional drug therapy (three or more drugs). During the procedure, a thin flexible tube called a catheter is inserted through a small incision in the groin and it is then weaved up to the renal arteries through a blood vessel in the leg. Once the catheter tip is placed inside of a renal artery, radiofrequency (RF) energy is delivered to reduce hyperactivity of the surrounding nerves, which causes the kidneys to produce less of the hormones that are responsible for chronic high blood pressure. Both of the renal arteries are treated during the procedure.

About Cordis Corporation

Cordis Corporation, part of the Johnson & Johnson Family of Companies, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company’s innovation, research and development, Cordis partners with clinicians to treat millions of patients who suffer from cardiovascular disease worldwide. More information about Cordis Corporation can be found at http://www.cordis.com.
1.     The World Health Report 2012. World Health Organization; 2012:58
2.   Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. Circulation. 2012;125:1594-6.
3.   Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood-pressure related disease, 2001. Lancet. 2008;371:1513-1518.
4.   The RENLANE™ Renal Denervation System is not available for sale or use in the United States.

Read more: Cordis Corporation Receives CE Mark for RENLANE Renal Denervation System to Treat Resistant Hypertension – FierceMedicalDevices http://www.fiercemedicaldevices.com/press-releases/cordis-corporation-receives-ce-mark-renlane-renal-denervation-system-treat-0#ixzz2u64hQ548

SOURCE

From: FierceMedicalDevices <editors@fiercemedicaldevices.com>
Reply-To: <editors@fiercemedicaldevices.com>
Date: Fri, 21 Feb 2014 18:00:51 +0000 (GMT)
To: <avivalev-ari@alum.berkeley.edu>
Subject: | 02.21.14 | J&J’s Cordis scores renal denervation CE mark

 

UPDATED on 2/7/2014

Renal Denervation Before the Fall. Guest: Deepak Bhatt

Samuel Z. Goldhaber, MD, Deepak L. Bhatt, MD, MPH

January 24, 2014

EDITORS’ RECOMMENDATIONS

VIEW VIDEO

http://www.medscape.com/viewarticle/819665?nlid=47583_1984&src=wnl_edit_medn_card&uac=93761AJ&spon=2

UPDATED on 1/23/2014

Covidien bails on renal denervation

January 21, 2014 by Brad Perriello

Covidien said it’s pulling the plug on its OneShot renal denervation device, citing the slow development of the hypertension market.

Covidien bails on renal denervation

Covidien (NYSE:COV) said it plans to wind down its OneShot renal denervation program, largely due to “slower than expected development of the renal denervation market,” meaning the end for a U.S. clinical trial of the high blood pressure device.

“This decision resulted from Covidien’s regular review of strategic programs and growth potential for various aspects of its product portfolio,” according to a press release. “Over the next several weeks, the company will collaborate with physicians and the renal denervation community to ensure existing OneShot patients are informed and the currently enrolling clinical trials are transitioned appropriately.”

The OneShot device already had CE Mark approval in the European Union for treating resistant hypertension in April 2012, when Covidien paid $60 million in cash and put another $170 million on the table in milestones.

The move means the closure of Covidien’s Rapid II trial, which was projected to enroll 253 patients, comparing treatment with the OneShot device with standard drug treatment in patients with resistant hypertension, according to the release.

SOURCE

http://www.massdevice.com/news/covidien-bails-renal-denervation

UPDATED on 1/21/2014

It’s not that Symple! The Rise (and Fall?) of Renal Denervation by Amy Siegel, http://s2nhealth.com

http://s2nhealth.com/2014/01/17/the-rise-and-fall-of-renal-denervation.html#.Ut7Mmxw8JaE

Clinical Trial Results will impact negatively the following players in the Global Supplier Ecosystem for Renal Denervation Systems:

US Campbell, CA Kona Medical is attempting to address these limitations. The system delivers energy from outside the patient to the renal nerves. Ultimately, the procedure will be a “no puncture,” noninvasive technique, compatible with technologies that will allow for temperature and lesion mapping. A noninvasive procedure will allow titration of the therapy— that is, the application of patient-specific dose fractions while monitoring therapeutic effect in between fractions. The basis of the technology is focused ultrasound, not high intensity (HIFU) as one might see and expect in the treatment of tumors, but low-intensity focused ultrasound (LIFU). The biologic underpinnings of this treatment are described in past literature for treating nerves using ultrasound. Kona noninvasive system. The system is depicted in a custom chair; another version of the system is compatible with a standard fluoroscopy or MRI table. Both ultrasound (through elastography and the evolution of temperature mapping and MRI) allow further imaging and analysis of the treatment area. The dose distribution surrounding the artery is that of an annular ring around the wall of the artery. Kona has shown in animal studies that a heat/vibratory cloud at one plane along the artery is highly effective at long-term inhibition of renal nerves with no visible effect on any portion of the artery at any time point.

US, Ronkonkoma, NY & Germany – Paradise  by ReCor Medical 6-F compatible catheter with a cylindrical transducer that emits ultrasound energy circumferentially, allowing for a more efficient renal denervation procedure First-in-human (15 patients at 3 months) BP drop, mm Hg -32/-16 at 3 mo. The ultrasound transducer lies within a low-pressure balloon that allows for self-centering of the transducer and gentle contact with the artery wall for uniform circumferential denervation. This means that nerves below the surface of the artery wall are damaged in 360° with a single emission. The balloon also enables cooled fluid to circulate during the energy delivery process, thereby cooling the endothelial wall and protecting it from any excessive heating that could be caused by other energy sources or designs. Preliminary F-I-M clinical data for PARADISE were reported previously at the “TRenD 2012” transcatheter renal denervation scientific meeting by cardiologist Thomas A. Mabin, M.D., Vergelegen Medi-Clinic, South Africa. The updated PARADISE data show that systolic blood pressure was reduced by a statistically significant average of 36 mm Hg in 8 patients at 90-days follow-up. The scientific literature demonstrates that only a 5 mm Hg reduction in BP results in a 14% decrease in stroke, a 9% decrease in heart disease, and a 7% decrease in mortality.

US, San Leandro, CA The Mercator Bullfrog by Mercator MedSystems, Inc. is a catheter-guided system designed to inject therapeutic agents directly, nonsystemically, and safely through blood vessel walls into adventitial tissues and has received US Food and Drug Administration 510(k) clearance. The Bullfrog catheter is tipped with a balloon-sheathed microneedle and is guided and inflated in a manner similar to an angioplasty catheter but with far lower expansion pressures (2 atm vs 6–20 atm) in vessels of 3 to 6 mm in diameter. It is compatible with 0.014-inch guidewires and 6-F introducer sheaths. When the desired injection site is reached, the balloon is inflated with saline and radiopaque contrast, securing the system for injection and sliding the microneedle through the vessel wall. Nonclinical studies have shown that the Bullfrog catheter is able to deliver up to 5 mL per injection into the renal artery adventitia with no apparent safety concerns. Guanethidine Ismelin) is delivered to the renal artery adventitia to accomplish sympathetic denervation. Given locally, guanethidine is known to induce an autonomic denervation directly and through an immune-mediated pathway. Mercator’s preclinical experiments have shown that guanethidine, injected at appropriate concentrations into the adventitial space around renal arteries, selectively ablates the nerves in the adventitia around the renal artery after a single, 20-minute procedure

J Neurosci. 1983;3:714-724

US – Laguna Hills, CA – V2 Radiofrequency Baloon by Vessix Vascular, Inc.Bipolar RF balloon catheter REDUCE-HTN pilot (10 patients)

Renal Denervation Technology of Vessix Vascular, Inc. been acquired by Boston Scientific Corporation (BSX) to pay up to $425 Million

http://pharmaceuticalintelligence.com/2012/11/08/renal-denervation-technology-of-vessix-vascular-inc-been-acquired-by-boston-scientific-corporation-bsx-to-pay-up-to-425-million/

BP drop, mm Hg -30/-11 at 1 mo V 2 catheter, a patented noncompliant balloon catheter with RF electrodes and thermistors mounted on the exterior of the balloon, and the proprietary V 2 bipolar RF generator. Once inserted into the renal artery, a 30-second inflation/treatment per renal artery delivers simultaneous RF therapy with independent temperature control to all electrode pairs. V 2 catheter is available in balloon diameters ranging from 4 to 7 mm, with a balloon length of 25 mm. Larger-diameter balloons have eight electrode pairs, and smaller-diameter balloons have four to six electrode pairs made of solid gold, which are biocompatible and facilitate good electrode contact with the renal arterial wall. In addition, the electrodes are radiopaque, allowing the V 2 catheter to be easily visualized under fluoroscopy. Beginning in the first quarter of 2012, the V 2 renal denervation system will be utilized in the company’s first international, multicenter clinical study: REDUCEHTN.

Israel, Tel Aviv – Tivus by Cardiosonic  A6-F transducer-tipped catheter, ultrasound energy (Animal data only) The solution for renal denervation is a high-intensity, nonfocused ultrasonic (US) catheter system named TIVUS (Therapeutic IntraVascular UltraSound) (Figure 3). By applying ultrasonic energy, the TIVUS technology enables remote, localized, controlled, and repeatable thermal modulation of the renal vessel wall tissue, resulting in safe renal nerve ablation. The remote thermal effect is located in the adventitia and perivascular region, with no thermal damage to the endothelium and media, therefore, preventing the development of vessel injury processes. Swine kidney tissue NE concentrations at 30- and 90-day follow-up have demonstrated successful renal denervation as witnessed by a 50% or more decline in tissue NE. Localized tissue thermal modulation/ablation, without damage to the blood vessel wall.

US, MN – SYMPLICITY HTN 2 by Medtronic   average office-based BP drops ofBP drop, mm Hg 32/12 mm Hg at six months in the SYMPLICITY HTN 2 trial, as reported by heartwire, with 84% of patients having had a >10-mm-Hg drop in systolic blood pressure from baseline. 14 points in 30 days and 27 points after 1 year. Available in Europe. Medtronic is the furthest ahead in its development process, predicting it will get Symplicity on the American market by 2015. catheter in the renal artery near each kidney to deliver radiofrequency energy to ablate the nerves. A single electrode in contrast to St. Jude’s mutli-electrode approach, is already on the road to FDA review with clinical trials approved last summer in the U.S. Symplicity system has been safely used in nearly 5,000 patients since commercialization

1/9/2014 – Pivotal US trial of Metronics’ Symplicity Renal Denervation System for Refractory Hypertension FAILED its Efficacy Endpoint

US, MN – EnligHTN 1 by  St Jude radiofrequency (RF) energy to create lesions (tiny scars) along the renal sympathetic nerves Mean office BP changes at one month in BP drop, mm Hg 28 systolic and -10 diastolic after 1 month (p<0.0001 from baseline), with 78% of patients having systolic BP drops of >10 mm Hg. St. Jude Medical’s (St. Paul, MN) announcement in late 2011 of the first patient to be enrolled in their first-in-man ARSENAL trial 15 at the University of Adelaide

Renal Denervation: EnligHTN IV Study Called Off and Potential Novel Indications – Diastolic Heart Failure

http://pharmaceuticalintelligence.com/2013/12/10/renal-denervation-enlightn-iv-study-called-off-and-potential-novel-indications-diastolic-heart-failure/

Ireland, Dublin – OneShot™ by Covidien acquisition of Maya Medical, Saratoga, CA New Irrigated RF Balloon Catheter secure first human use for the device in the third quarter of this year, followed by a CE mark for the drug-resistant hypertension treatment in 2013. Presumably, a filing with the FDA would follow that. the OneShot renal denervation system, was born out of the company’s extensive expertise in radiofrequency (RF) ablation and percutaneous coronary interventions (PCI), drawing upon the benefits and best practice standards of each distinct yet complementary clinical discipline. The result is a unique product platform that could further accelerate the paradigm shift in the management of resistant hypertension. consistent with Maya’s balloon-based approach is the ability to deliver predictable apposition of the RF electrode to the vessel wall for more controlled targeted delivery of the RF energy. By offering a more reliable single-treatment approach coupled with enhanced ease of use and reduced procedure times, Maya Medical believes its OneShot renal denervation system has the potential to significantly expand clinical adoption

http://bmctoday.net/evtoday/2012/02/article.asp?f=renal-artery-denervation-a-brave-new-frontier

1/21/2014

Covidien said it’s pulling the plug on its OneShot renal denervation device, citing the slow development of the hypertension market.

Covidien bails on renal denervation

Covidien (NYSE:COV) said it plans to wind down its OneShot renal denervation program, largely due to “slower than expected development of the renal denervation market,” meaning the end for a U.S. clinical trial of the high blood pressure device.

“This decision resulted from Covidien’s regular review of strategic programs and growth potential for various aspects of its product portfolio,” according to a press release. “Over the next several weeks, the company will collaborate with physicians and the renal denervation community to ensure existing OneShot patients are informed and the currently enrolling clinical trials are transitioned appropriately.”

The OneShot device already had CE Mark approval in the European Union for treating resistant hypertension in April 2012, when Covidien paid $60 million in cash and put another $170 million on the table in milestones.

http://www.massdevice.com/news/covidien-bails-renal-denervation

US, Natick, MA Boston Scientific lags behind in the race to cash in on hypertension-treating devices, incoming CEO Michael Mahoney said at a Monday conference that it has a plan for its RDN renal denervation system. As MassDevice reports, Mahoney said Boston Sci expects to secure first human use for the device in the third quarter of this year, followed by a CE mark for the drug-resistant hypertension treatment in 2013.

Renal Denervation Technology of Vessix Vascular, Inc. been acquired by Boston Scientific Corporation (BSX) to pay up to $425 Million

http://pharmaceuticalintelligence.com/2012/11/08/renal-denervation-technology-of-vessix-vascular-inc-been-acquired-by-boston-scientific-corporation-bsx-to-pay-up-to-425-million/

Heartwire Reported on December 09, 2013

On 1/9/2014 we post that

Pivotal US trial of Metronics’ Symplicity Renal Denervation System for Refractory Hypertension FAILED its Efficacy Endpoint

In the Press

Medtronic to weigh future of Symplicity renal denervation system after US trial failure

(Ref: Yahoo!News, The Wall Street Journal, StreetInsider, Medtronic)

January 9th, 2014
By: Katie Bell

Medtronic said Thursday that a pivotal US trial of its Symplicity renal denervation system for treatment-resistant hypertension failed to meet its main efficacy endpoint. The company noted that based on the results of the SYMPLICITY HTN-3 study, it will form an independent panel “to make recommendations about the future of the global hypertension clinical trial programme, as well as provide advice on continued…access to the Symplicity technology in countries with regulatory approvals.”

Depending on the panel review, the company said that it plans to suspend enrollment in the three countries where renal denervation hypertension studies are under way, including, the SYMPLICITY HTN-4 trial in the US, the HTN-Japan study in Japan and the HTN-India trial in India. Chief medical officer Rick Kuntz remarked that “we believe this course of action…will help us thoroughly evaluate these findings and determine the appropriate next steps for renal denervation therapy.”

The Symplicity system received CE mark approval in 2008, with Medtronicannouncing last month that regulators in Europe and Australia cleared the Symplicity Spyral catheter and Symplicity G3 radio frequency generator. The device maker said Thursday that it is evaluating the value of its renal denervation assets and believes “a one-time impairment charge in the future will be likely,” but reiterated its revenue outlook and diluted earnings per share guidance for fiscal 2014.

The SYMPLICITY HTN-3 trial randomised 535 patients with treatment-resistant hypertension and systolic blood pressure higher than 160 mmHg to a treatment or a control group, with all participants continuing to take blood pressure medications. The primary endpoints of the study were the change in office blood pressure from baseline to six months and incidence of major adverse events. Co-principal investigator Deepak L. Bhatt noted that the study “met its primary safety endpoint related to the incidence of major adverse events one month following randomisation and renal artery stenosis to six months.”

This Open Access Scientific Journal has covered all the major developments reported on Renal Denervation since its inception

The Archive for Renal denervation

http://pharmaceuticalintelligence.com/category/cardiac-and-cardiovascular-surgical-procedures/renal-denervation/

Search Results for Renal Denervation

http://pharmaceuticalintelligence.com/?s=Renal+denervation

For the ORIGINAL work on 

Renal Sympathetic Denervation: Updates on the State of Medicine

the Readers is called to go to the ORIGINAL SOURCES listed below:

Intravascular Stimulation of Autonomics: A Letter from Dr. Michael Scherlag

http://pharmaceuticalintelligence.com/2012/09/02/intravascular-stimulation-of-autonomics-a-letter-from-dr-michael-scherlag/

Imbalance of Autonomic Tone: The Promise of Intravascular Stimulation of Autonomics

http://pharmaceuticalintelligence.com/2012/09/02/imbalance-of-autonomic-tone-the-promise-of-intravascular-stimulation-of-autonomics/

Interaction of Nitric Oxide and Prostacyclin in Vascular Endothelium

http://pharmaceuticalintelligence.com/2012/09/14/interaction-of-nitric-oxide-and-prostacyclin-in-vascular-endothelium/

Absorb™ Bioresorbable Vascular Scaffold: An International Launch by Abbott Laboratories

http://pharmaceuticalintelligence.com/2012/09/29/absorb-bioresorbable-vascular-scaffold-an-international-launch-by-abbott-laboratories/

The Molecular Biology of Renal Disorders: Nitric Oxide – Part III

http://pharmaceuticalintelligence.com/2012/11/26/the-molecular-biology-of-renal-disorders/

Treatment of Refractory Hypertension via Percutaneous Renal Denervation

http://pharmaceuticalintelligence.com/2012/06/13/treatment-of-refractory-hypertension-via-percutaneous-renal-denervation/

Renal Denervation Technology of Vessix Vascular, Inc. been acquired by Boston Scientific Corporation (BSX) to pay up to $425 Million

http://pharmaceuticalintelligence.com/2012/11/08/renal-denervation-technology-of-vessix-vascular-inc-been-acquired-by-boston-scientific-corporation-bsx-to-pay-up-to-425-million/

Read Full Post »

« Newer Posts - Older Posts »